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ABSTRACT 
Background: The Mexican population has been found to exhibit an environmental and 
genetic predisposition to develop blood lipid disorders [1, 2]. The fatty acid desaturase (FADS) 
gene cluster encodes two key enzymes which are involved in the synthesis of long-chain 
polyunsaturated fatty acids (PUFA). Delta-5 desaturase (D5D) and Delta-6 desaturase (D6D) are 
encoded by FADS1 and FADS2, respectively. FADS gene cluster polymorphisms have recently 
been determined to be associated with high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) levels in Europeans [3]. Moreover, the dietary intake of 
PUFAs affects FADS-blood lipids interactions [4]. Gene-nutrient interactions and individual 
genetic variations of the FADS gene cluster have not been described in young Mexicans to date.  
Objectives: The first aim was to report genetic associations between FADS1-rs174546 and 
FADS2-rs1535 polymorphisms and blood lipid profiles in Mexican college-age students. The 
second aim was to determine whether dietary intake of omega-3 and omega-6 PUFAs modified 
genetic associations between the FADS gene cluster and lipid profiles.  
Methods: Body mass indexes (BMI), blood lipid profiles, dietary intakes of omega-3 and 
omega-6 fatty acids, and genotypes in the FADS gene cluster were evaluated in 462 individuals 
from the “UP AMIGOS” cohort, aged 18-25 yrs. FADS-SNPs were in Hardy-Weinberg 
equilibrium with a minor allele frequency of 0.29 and 0.28 for rs174546 and rs1535, 
respectively. All of the data was analyzed using SAS 9.3 (SAS Institute Inc., NC, USA), 
assuming a significance level of p<0.05 for multiple comparisons. Non-normal distributed 
variables were log transformed prior to analysis. The primary analysis was conducted using 
general linear regression models to examine associations between FADS SNPs and the blood 
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lipid profiles adjusted for sex, age and BMI. A secondary analysis tested the impact of dietary 
intake of omega-3 (g/d) and omega-6 (g/d) on the association between FADS SNPs and the lipid 
profiles adjusted for sex, age, BMI and total calorie intake. 
Results: Carriers of the minor C-allele of FADS1-rs174546 and A-allele of FADS2-rs1535 
had significantly higher LDL-C, TC and non-HDL-C concentrations compared with 
homozygotes for the major allele (T and G alleles, respectively). No significant associations 
were observed between the FADS genotypes and HDL-C, TG and VLDL concentrations. 
Moreover, BMI status has a strong impact on the FADS genotype and the lipid profile. Second, a 
significant association was observed between FADS1/FADS2 and dietary intake of omega-3, but 
this was not the case for omega-6 with respect to LDL-C levels. In addition, as a categorical 
variable, carriers of the C-allele were associated with lower LDL-C among those with lower 
intakes of omega-3. 
Conclusion: Carriers of the minor allele of FADS1/FADS2 exhibited higher levels of 
atherogenic lipoproteins such as higher LDL-C. Moreover, FADS polymorphisms interact with 
dietary omega-3 to effect plasma cholesterol concentrations, which should be investigated further 
in future studies.  
Future directions: There has been a documented rapid increase in the prevalence of 
Mexican college-age students who are overweight and obese coupled with a high prevalence of 
dyslipidemias [5-9]. We propose a new approach for identifying individuals who are at risk for 
dyslipidemias. This approach investigates potential gene-nutrient interactions that may provide 
insight into potential future therapies and dietary intervention strategies for preventing or 
delaying cardiovascular disease. 
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CHAPTER 1 
INTRODUCTION 
In 2012, Mexico was found to have the highest levels of obesity in North America. 72% of 
Mexican adults were overweight (~40%) or obese (32.8%) [10-12]. In addition, 16.7% of 
preschool children, 26.2% of school children and 30.9% of adolescents in Mexico were found to 
be overweight or obese [10]. More particularly, among college-aged students the prevalence of 
being overweight and obese increased from 13.2% to 37.3% from 1994 to 2008 [13].  
Mexico is currently facing an increase in non-communicable diseases such as diabetes, 
cardiovascular disease (CVD) and chronic kidney disease, and this has impacted the national 
health-care budget [14]. Recent evidence concerning the economic burden of obesity in the U.S. 
reported significantly higher health care expenses and expenditures for obese children compared 
with their normal-weight peers [15]. The annual expenses associated with childhood obesity in 
the U.S. were ~$14.1 billion [15]. In Mexico, the total costs of obesity-related diseases was 
estimated to be $806 million in 2010, and this is projected to increase to $1.2 billion and $1.7 
billion in 2030 and 2050, respectively [16]. 
Over half of all deaths from CVD in Mexico can be attributed to dyslipidemia [17]. The most 
common lipid disorders among Mexican adults aged 20 to 69 years were: low high-density 
lipoprotein cholesterol (HDL-C) (60.5%), high low-density lipoprotein cholesterol (LDL-C) 
(46%), high total cholesterol (TC) (43.6%), and high triglycerides (TG) (31.5%) [18]. Similar 
trends have been reported in the younger age groups, where 13.5% of children and adolescents, 
and 51.3% of young adults had low HDL-C [19-22]. It is well-known that the management of 
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lipids is essential for significantly reducing and preventing cardiovascular events, and consuming 
a balanced diet is a key factor in prevention [23-25]. 
The American Heart Association (AHA) provides dietary recommendations for promoting an 
overall healthy lifestyle with the goal of reducing the risk of CVD. These recommendations 
primarily involve nutritional adequacy and energy balance [26]. Dietary recommendations 
include consuming a diet rich in vegetables and fruits, choosing whole-grains, limiting the intake 
of dietary fat to 20-35% of energy intake, limiting the consumption of saturated fat (SFA) to 7% 
of total energy intake, increasing the consumption of n-3 polyunsaturated fatty acids (PUFA) and 
limiting intake of trans fats [27]. However, the recommended nutritional goals that can help 
prevent chronic diseases are not being met in children and adolescents. In a study across thirty 
countries including Mexico, less than half of the children and adolescents met the SFA and 
PUFA intake goals established by AHA [28]. 
The current Mexican diet is characterized by high levels of consumption of soft drinks, 
refined grains, corn tortillas, pastries and low levels of consumption of dairy products, seafood 
and whole grains [29]. In addition, the excessive intake of SFA and PUFA have been reported 
[30]. This dietary pattern has been associated with the high prevalence of dyslipidemia and 
central obesity among both younger Mexicans and adults [31, 32]. In contrast, the traditional 
(prudent) diet which involves high levels of consumption of fruits, vegetables, and legumes, and 
low levels of consumption of pastries and cereals has been associated with lower body mass 
index (BMI) and low TG [12].  
Diet is one of a number of factors which affect blood lipids, and genetics also plays a key 
role [33]. Several studies have found that the Mexican population has a genetic predisposition for 
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dyslipidemias, particularly low HDL-C and high TG levels [1, 34-38]. However, research on 
identifying polymorphisms associated with LDL-C levels is lacking for the young Mexican 
population.  
Genome-wide analysis (GWA) studies conducted in Europeans have found that blood lipid 
profiles are highly heritable, including ~40-60% for HDL-C, ~40-50% for LDL-C and ~35-48% 
for triglycerides [39, 40]. Currently, 95 genetic loci have been determined to be associated with 
plasma blood lipids which are also associated with coronary heart disease [41]. However, genetic 
variations in the lipid loci explain only ~12% of the overall variation of plasma lipids [41]. 
Blood lipid levels have been reported to have a strong genetic component, with heritability as 
high as 80% in childhood [42]. Childhood serum lipid levels have been shown to predict lipid 
measurements in adulthood [43-46]. A longitudinal study of Finnish children and adolescents 
estimated the effect of individual single-nucleotide polymorphism (SNPs) on lipids 
measurements. This study found that 26.7% of the total variance of HDL-C in males, and 21.9% 
in females, was explained by SNPs in children (age 3 to 6 years old), and 10% in adults over 20 
years old [47]. 
The Mexican population has a genetic predisposition toward low HDL-C and high serum 
triglycerides levels [1, 34, 35, 37, 48], and 65% of the adult population has at least one type of 
dyslipidemia [18, 49]. Taking this into consideration leads to the notion that studying the effect 
of genetic variations which influence lipid levels in a young population could provide useful 
information for the early detection of lipid disorders and the increased risk of coronary heart 
disease. 
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Epidemiological evidence supports the contention that there are health benefits to be derived 
from including omega-3 [alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid, (DHA)] in the diet [50]. Human trials and dietary interventions 
demonstrate that increasing the amount of omega-3 in the diet significantly reduces blood lipid 
profiles, insulin sensitivity and the risk of CVD [51-55]. These benefits have also been described 
in the Mexican population [56-58]. In particular, Mexican obese children respond better to a 
dietary intervention involving omega-3 (1.8g/d omega-3, EPA + DHA) than treatment with 
metformin [56]. However, more than 50% of the Mexican population consumes an insufficient 
intake of PUFAs and an excessive intake of SFA [30]. 
In addition to dietary sources, PUFAs can also be derived endogenously from precursor 
essential fatty acids, linoleic acid (LA; C18:2n-6) and alpha-linoleic acid (ALA; C18:3n-3), by 
two enzymes: delta-5 (D5D) and delta-6 (D6D) desaturases. These enzymes are encoded by 
FADS1 and FADS2 genes, respectively in the fatty acid desaturase (FADS) gene cluster [59]. 
The FADS gene cluster is thus a good candidate for genetic association studies which focus on 
determining gene-nutrient interactions which may affect individual variations of blood lipid 
levels. Gene-nutrient interaction studies of the young Mexican population have been lacking so 
far. 
Several studies have identified the genetic variations in the FADS gene cluster that not 
only influence fatty acid metabolism [60], but also influence glucose metabolism and other blood 
lipids such as TC, low LDL-C and high TG [61-63]. Several studies have identified that carriers 
of the minor alleles of single-nucleotide polymorphisms (SNPs) in the FADS gene cluster are 
associated with higher TC and TG, and lower HDL-C levels [61-63]. In addition, PUFAs have 
been shown to have genetic variants which interact with genetic variants FADS to affect blood 
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lipids [64-67]. Moreover, the intake of dietary fatty acids modifies the effect of FADS genotype 
categories on blood lipids [4, 68-71].  
Gene-nutrient studies have shown that dietary fatty acids interact with a wide variety of SNPs 
in order to modulate TC and LDL-C levels [52, 72-74]. More particularly, SNPs in the FADS 
gene cluster have been shown to affect the activities of the enzymes which metabolize essential 
fatty acids in order to modulate the genetic risk in CVD [68, 75-78]. Therefore, it is of interest to 
identify and characterize the SNPs in the FADS gene cluster which may be mediated by dietary 
fat intake.  
Study goals 
The Mexican population has a high prevalence of dyslipidemias due to their genetic 
background of the population [1, 34, 37].  
In particular, the prevalence of dyslipidemias among college students pointed us to our first 
goal: identifying genetic variations in the FADS gene cluster associated with blood lipid levels. 
Moreover, population-based research regarding the association between the FADS genotype, 
dietary fatty acids intake (e.g. omega-3 and omega-6), and serum lipid relationships in young 
Mexican students is incomplete. Therefore, our second goal was to examine whether or not 
dietary fat intake modifies the association between SNPs in the FADS gene cluster and blood 
lipid concentrations.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Lipoprotein metabolism 
Lipoproteins are large macromolecular complexes which are composed of a core of 
cholesterol esters and triglycerides (TG) surrounded by phospholipids and free cholesterol [79]. 
The plasma lipoproteins are divided into five major categories based on their relative 
densities: chylomicrons (CM), very-low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). The 
size and density of a lipoprotein depends on the content of lipids and apolipoproteins per particle. 
HDL is the smallest and densest lipoprotein (1.063-1.210 g/mL). CM (triglyceride-rich 
lipoprotein) and VLDL are the largest and least dense lipoprotein particles, and have densities 
that are less than 1.006 g/mL [79]. 
Other particles associated with lipoproteins are known as apolipoproteins. There are four 
types of apolipoproteins: ApoA-1, ApoB, ApoC and ApoE. These proteins have four major 
functions: (1) assembly and secretion (ApoB100 and apoB48); (2) structure (ApoB, ApoE, 
ApoAI, ApoAII); (3) coactivators or inhibitors of enzymes (Apo AI, CI, CII, CIII); and (4) 
ligands for cell surface receptors (Apo-AI, B100, E) [79]. 
ApoA-I is synthesized in the liver and intestine and is found in all HDL particles. Two-thirds 
of all HDL particles are of the Apo-AII type, the second most abundant type of HDL particle 
[79]. ApoB is the major structural protein of the chylomicrons VLDL, IDL, and LDL. There are 
two types of ApoB: ApoB-48, which is present in CMs, and ApoB-100 which is present in 
VLDL, IDL or LDL. ApoE is present in CM, VLDL and IDL, and plays a critical role in the 
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metabolism and clearance of triglycerides-rich particles. There are three types of ApoC: ApoC-I, 
ApoC-II and ApoC-III, all of which participate in the metabolism of triglycerides-rich 
lipoproteins [79]. 
The main function of lipoprotein particles is the transport of TG, cholesterol and fat-soluble 
vitamins from the liver to the peripheral tissues and the transport of cholesterol from the 
peripheral tissues to the liver [79]. In addition, lipoproteins play an essential role in the 
absorption of cholesterol, fatty acids and fat-soluble vitamins from the diet [79]. Most plasma 
triglycerides are transported in CM or VLDL, and most of the plasma cholesterol is carried in the 
form of cholesterol esters in LDL and HDL [79]. 
The transport of fatty acids (FA) in the body is thought to involve two pathways. The first 
pathway is an exogenous pathway involved in the absorption and transport of dietary lipids from 
the intestine to peripheral tissues and then back to the liver. The second pathway is an 
endogenous pathway involving the hepatic secretion of ApoB-containing lipoproteins and their 
metabolism. 
Exogenous pathway 
After a meal, most lipids, like other macronutrients (carbohydrates and proteins), are broken 
down into smaller compounds for absorption in the gastrointestinal tract. In the intestinal lumen, 
free fatty acids (FFA) and 2-monoacylglycerols (MAG) are taken up by the enterocytes via 
passive diffusion and specific transporters such as FABPpm, FATP4 and FAT/CD36, while 
cholesterol is transported by an active transporter Niemann-Pick C1 like 1 protein (NPC1L1) 
[80]. 
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Once inside the enterocyte, FFA and MAG are reassembled into triglycerides (TGs), and 
cholesterol is transformed into cholesterol-esters [80]. New TGs are packaged with 
phospholipids and Apo B48 to form CM, and are secreted from the intestinal cells into the 
lymphatic system where they enter the bloodstream via the thoracic duct. HDL donates ApoC-II 
and ApoE to the nascent CM, and HDL delivers FFA to cells in the heart, skeletal muscle and 
adipose tissue [80, 81]. Once it enters the blood, the enzyme lipoprotein lipase (LPL) that is 
attached to the inside wall of most cells is activated by ApoC-II in order to transfer TGs from the 
CM to the cells for energy or storage [82]. Then, smaller CMs called CM remnant travel back to 
the liver to be excreted out the body. 
Endogenous pathway 
The endogenous pathway transports fat from the liver to the peripheral tissues, and then 
returns to the liver. In the liver, TG-rich lipoproteins are packed into molecules known as VLDL 
which enter the circulatory system [82]. VLDL is a triglyceride-rich lipoprotein that is smaller 
than CMs. Both are similar in protein composition, but contain ApoB-100 instead of ApoB-48 
and have a high ratio of cholesterol to TG [82]. 
In the peripheral tissues, lipoprotein lipase (LPL) hooks up with VLDL and TGs are released, 
and become intermediate-density lipoproteins (IDL). Hepatic lipase (HL) and LPL then remove 
additional TGs from IDLs in order to generate low-density lipoproteins (LDLs) [82]. LDL-C and 
CM remnants are removed from the blood by the liver [82]. 
Another important pathway in the metabolism of lipoproteins is the uptake of cholesterol 
from peripheral tissues. This is known as reverse cholesterol transport, and it is accomplished by 
HDL particles [82]. The intestine and liver synthesize ApoA-I in order to assemble nascent HDL. 
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When nascent HDL is in circulation, it collects free cholesterol from the cells and becomes 
mature HDL, and transports free cholesterol from the peripheral tissues back to the liver. The 
cholesterol that is found inside HDL lipoproteins is esterified into cholesterol-esters by HDL 
associated lecithin-cholesterol acyltransferase (LCAT) [82]. When in circulation, cholesterol 
ester transfer protein (CETP) exchanges TG from VLDL for cholesterol esters of HDL. While in 
the liver, HL hydrolyses TGs from HDL, which induces the formation of smaller particles of 
HDL which restarts the reverse cholesterol transport pathway. 
2.2 Lipoprotein and atherosclerosis 
Cardiovascular disease (CVD) refers to any disease that affects the cardiovascular system. 
CVD had diverse causes, and atherosclerosis and hypertension are the most common causes [83]. 
Atherosclerosis is the accumulation of fatty materials in the artery walls, and the accumulation of 
lipids which is converted from fibromuscular cap to form what is known as fibrous 
atherosclerotic plaque [84-86]. When LDL is not taken up by the body, it is oxidized by free 
radicals, and the scavenger cells (macrophages and white cells) remove oxidized LDL from 
circulation [82]. Over time, high concentrations of LDL in the circulatory system lead to the 
accumulation of cholesterol in the scavenger cells and accumulations in the inner lining of the 
arteries. This can produce conditions such as a heart attack, stroke and other cardiovascular 
disease [83, 87]. 
Since the 1980s, atherosclerosis plaque and CVD have been determined to be associated with 
high cholesterol levels. The Framingham Study’s researchers analyzed the association between 
mortality and serum cholesterol values for 4,374 participants who were followed for 30 years 
[88]. This study found that for every 10 mg/dL increase in blood cholesterol levels, CVD deaths 
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increased by 9% [88]. Furthermore, the Multiple Risk Factor Intervention Trial (MRFIT) 
confirmed that 49% of all CVD deaths were associated with serum cholesterol levels of 180 
mg/dL or above [89]. More recent cohort studies such as the Seven Country Study [90] and a 
meta-analysis [91] concluded that an increase of 1 mmol/l (38.67 mg/dL) in blood cholesterol 
was strongly associated with a 20-35% increase in CVD risk [90], and with a 12% increase in 
CVD mortality risk [91]. In addition, cohort and case-control studies highlight that low HDL-C 
is involved in CVD and mortality [92-95].  
CVD does not usually occur until the fifth or sixth decade of life [96]. However, the 
atherosclerosis process is known to begin early in childhood [95, 97, 98]. The Bogalusa Heart 
Study has demonstrated that the occurrence of elevated cholesterol levels during childhood puts 
them at risk for having high adult cholesterol levels [99, 100].  
Atherogenic dyslipidemia, which is characterized by high TG, low HDL-C and high LDL-C, 
is commonly found in obese children and adolescents [84, 101]. The early stage and progression 
of atherosclerosis in youths is associated with dyslipidemia and obesity [43, 95].  
Hypertriglyceridemia in obesity is a consequence of increased fasting and postprandial TG 
which leads to elevated levels of free fatty acids (FFA). The liver processes those FFA, and 
increases the production of VLDL, and CETP later increases the exchange of cholesterol esters 
and TG between VLDL and HDL, and LDL. Furthermore, HDL concentrations decrease and 
small dense LDL increases [9]. As mentioned above, small dense LDL become trapped on the 
arterial walls and enhances its atherogenicity [84, 93]. 
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2.3 Diet and CVD risk factors 
Diet is an important environmental factor in the prevention of cardiovascular disease (CVD) 
[102-105]. Evidence from several epidemiological studies reflect that omega-3 fatty acids such 
as EPA and DHA (2-4g/day) reduce TG by 25-30%, with greater decreases found among 
subjects with baseline hypertriglyceridemia [106, 107]. On the other hand, high SFA intake has 
been confirmed to correlate with an increased incidence of CVD [25, 102, 103, 108].  
Data from clinical trial show that restriction of total fat intake (~7%) can reduce total TC by 
20 mg/dl, TG by 40 mg/dL, and increase HDL-C by 5 mg/dL [109]. Moreover, the evidence 
suggests that reduced SFA intake reduces the risk of CVD events by 14% [105]. Current 
guidelines recommend that 20% to 35% of daily caloric energy come from dietary fat, and 
specifically recommend limiting the consumption of saturated fats to no more than 7-10% of 
total caloric energy, and less than 300 mg/day of cholesterol [110]. Western diets containing 
excessive SFA and very little n-3 (polyunsaturated fatty acid PUFAs) are associated with 
increases in TC and LDL-C concentrations [102, 104, 105].  
The Lyon Diet Heart Study showed that the Mediterranean diet reduces the rate of recurrence 
of myocardial infarction and reduces mortality [111]. Moreover, the Diet and Reinfarction Trial 
(DART) supported the contention that a diet that is rich in eicopentaecoic acid (EPA; C20:5n-3) 
was associated with 29% reduction in all-cause mortality, and reduced the incidence of ischemic 
complications due to atherosclerosis [112]. In addition, a multi-ethnic cohort of 2,837 U.S adults 
showed that high levels of circulatory EPA and docosapentaenoic acid (DHA; C22:6n-3) were 
inversely correlated with a lower incidence of CVD [55]. Current dietary recommendations 
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advise reducing the intake of SFA and trans-fatty acids (TFA) and increasing the intake of 
PUFAs in order to reduce CVD risk [113].  
As mentioned above, a diet that is high in SFA is associated with increased risk of 
dyslipidemia and obesity [114, 115]. A study which assessed the intake of fats by children and 
adolescents in thirty countries around the world show that less than half of the children and 
adolescents met the minimum dietary recommendations for SFA and PUFAs intake [28]. Table 1 
shows dietary intakes in adolescents (aged 11-18 years) around the world. 
A recent study performed by the Nutrition and Chronic Diseases Expert Group found that, in 
Central Latin America, the intake of saturated fat increased by 0.5% E (0.1 to 1.0% E/day) and 
the intake of omega-6 increased by 1.3% E (0.6 to 2.1% E/day) between 1990 and 2010 [116]. 
On the other hand, the consumption of omega-3, particularly in in Mexico, is less than 50mg/day 
[116]. Notably, human intakes of trans fats are higher in Mexico, Canada and Egypt (>2% E) 
compared with other nations [116].  
The Mexican National Health and Nutrition survey of 2006 reported that 61% of human 
energy intake comes from carbohydrates, and 25% of energy intake comes from total fat, and 
this constitutes a large part of the typical Mexican adult diet [117]. More particularly, high 
saturated fat consumption (SFA) among children and adolescents (0.5g/d or 0.04% E) is a major 
public concern regarding the Mexican population [30]. 
A cross-sectional study of Mexican school-aged children (8-10years) in Mexico City found 
that high intake of SFA (~12% E) was significantly associated with higher diastolic hypertension 
[118]. Therefore, future research is needed to explore the association between the intake of fatty 
acids and the widespread prevalence of dyslipidemias among Mexican college students. 
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LA is the primary PUFA found in significant quantities in many vegetable oils (e.g., corn, 
safflower, soybean and sunflower oil) and in products made from such oils (e.g., margarines). 
The PUFA-rich oils are divided into those oils which have small amounts of ALA and high 
levels of LA, and those which have high levels of ALA. Flaxseed and canola are rich in ALA, 
whereas soy and walnut oil provide sufficient ALA as well as LA [143]. On the other hand, olive 
oil and avocado oils are oils rich in monosaturated mono-unsaturated fatty acids.  
In Mexico, the main sources of LA and ALA are chicken, eggs, corn tortillas, vegetable oils 
(e.g., corn, soy, sunflower, safflower or olive oil), and sweet breads [144]. Dietary fatty acids (n-
3) intake includes DHA, ALA and EPA, all of which are found in chicken, eggs, salmon, fresh 
fish. However, their consumption in Mexico is lower than foods with n-6 fatty acids [144]. 
A cross-sectional study of Mexican 20-70 years of age found that dietary patterns high in 
refined cereals, pastries, corn tortillas and sugared sodas were associated with significant 
increases in BMI [31] and dyslipidemia (low HDL-C and high TG) [32].  
Dietary fat mirrors fatty acid composition in serum lipids, erythrocyte membranes and 
adipose tissue [145]. The activity of the delta-5 (D5D), delta-6 (D6D) and enlogases play an 
important role in several metabolic risk factors [146, 147]. 
 
 
 
 
 14 
 
Table 1. Dietary fat intake in adolescents 12-18 years old in 8 countries† 
Country 
Age 
(years) 
Subjects 
(n) 
TFA 
(% E) 
SFA 
(% E) 
MUFA  
(% E) 
PUFA  
(% E) 
Australia† 12-18 1086 32.9 ± n.a 14.0 ± n.a 11.7 ± n.a 4.5 ± n.a 
Costa Rica† 12-18 275 31.7 ± 6.5 11.4 ± 3.3 3.6 ± 3.0 5.7 ± 2.9 
India† 13-18 797 34.0 ± 6.0 14.7 ± 2.5 11.6 ± 1.8 4.9 ± 1.3 
Israel† 12-18 5760 33.3 ± 4.7 11.3 ± 2.4 10.3 ± 2.2 6.9 ± 1.7 
Spain† 14-24 1576 39.9 ± 4.0 13.0 ± 2.0 16.4 ± 2.0 5.2 ± 1.0 
U.K† 11-18 864 35.7 ± 4.7 13.8 ± 2.2 11.8 ± 2.0 6.3 ± 1.6 
USA† 12-19 2115 33.2 ± 15.1 11.5 ± 4.3 12.1 ± 7.8 6.6 ± 3.2 
Mexico* 12-19 7731 26.6 ± 0.17 10.7 ± 0.08 6.5 ± 0.05 9.4 ± 0.06 
Data is presented in mean and standard deviation as percentage of energy (% E); n/a, not 
available. †Table was adapted from R. K. Harika et al. "Fatty acid intakes of children and 
adolescents are not in line with the dietary intake recommendations for future cardiovascular 
health: a systematic review of dietary intake data from thirty countries," Br J Nutr, vol. 106, pp. 
307-16 [28].*Dietary fat in Mexican adolescents in percentage of energy and standard error of 
the mean (Ramirez-Silva, Villalpando et al. 2011). 
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2.4 Impact of genotype on the blood lipid profiles 
Among the environmental factors discussed in the previous section, blood lipid levels are 
influenced by multiple genetic factors. Other factors such as age, gender, diet and obesity 
modulate the association between genes and lipid traits. 
Since the introduction of genomics techniques, our understanding of the genetic basis of 
CVD has increased. Genome-wide association studies (GWAS) enable the scanning of the entire 
genome in order to identify the genes and/or loci which are significantly associated with CVD. 
The GWAS has identified genes and/or loci associated with atherosclerosis [119], inflammation 
[120], and lipid traits [40, 121, 122].  
GWAS has been used to determine that blood lipid profiles are highly heritable, including 
~40-60% for HDL-C, ~40-50% for LDL-C and ~35-48% for triglycerides [39, 40]. However, 
genetic variation only explains ~12% of the overall variation of plasma lipids [41, 123]. 
There are several example of GWAS having been used to identify genes that have been 
implicated for CVD, including blood pressure [124] and ischaemic stroke [125]. Moreover, 
GWA studies have identified candidate genes suspected of influencing plasma lipid 
concentrations that may contribute to the pathogenesis of atherosclerosis [33, 40, 122, 126].  
Today, 52 genes for HDL-C, 42 genes for LDL-C, 59 genes for TC, and 39 genes for TG 
have been identified [127]. More GWAS have replicated these results in non-Hispanic Whites, 
non-Hispanic Blacks, Mexican-Americans, Hispanics and people of European descent [123, 128, 
129]. Furthermore, a GWAS determined that there are many loci which are associated with CVD 
risk in children. The Bogalusa Heart Study (BHS) is a longitudinal study of participants of 
European ancestry which identified seven associations that increased the risk of CVD [130]. 
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GWAS has been a particularly useful approach for identifying loci that influence the 
development of CVD, and for identifying genetic risk factors in children. However, GWAS 
requires replication and validation of the findings in additional population samples, so the 
GWAS approach might have limited applicability. 
Although the genetic variations of genes may be related to the development of CVD later in 
life, the combination of genes, environmental, and behavioral factors is the key to preventing or 
delaying the onset of CVD.  
In addition to candidate gene studies, some GWAS tests have identified genes that are 
associated with energy and macronutrient intakes. A meta-analysis of GWAS associated with the 
intake of macronutrients from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) found that genetic variants in the FTO gene were associated with 
protein intake and SNPs on chromosome 19 were associated with the intake of carbohydrates and 
fat [131]. Similarly, the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) 
which was performed using Black and White subjects who had linked regions in the 1p21 and 
20q and dietary energy and nutrient intakes [132]. As regards Hispanic children, a GWAS 
identified chromosome 18q as being related to physical activity and carbohydrate intake [133].  
Although recent GWAS have identified numerous genetic risk factors for complex diseases, 
including plasma lipids, some technical issues are relevant and need to be described. GWAS 
detected small effects associated with common variants, and used a large sample size of 
individuals. It requires replications of significant findings, and has the potential for producing 
false negative results [134]. Thus, the genotyping of selected SNPs is a better approach for 
genetic studies. 
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Single-nucleotide polymorphism (SNP) is a variation of a single base pair which represents 
the most frequent form of polymorphism in the human genome. The term minor allele is reserved 
for variants where the frequency exceeds 1% [134]. The data that is available from the 
International HapMap Project shows that many SNPs exhibit a high correlation between SNP 
genotypes and selected markers due to their shared evolutionary history [135]. This concept for 
finding efficient sets of SNPs is known as tagging SNPs (TagSNPs). The following section will 
discuss the most relevant findings concerning using the TagSNPs approach in gene-nutrient 
studies. 
Current research focuses on finding interactions between diets and genetic variants affecting 
CVD risk, and obesity is widely recognized as contributor to CVD risk. 
A large cohort from three independent populations include the Framingham offspring Study, 
the Genetics of lipid lowering drugs and diet network (GOLDN) study, and the Boston-Puerto 
Rican CPHHD study. All of these studies found that of C-allele of the APOA2 SNP consuming 
high intakes of SFA, were strongly associated with body mass index (BMI) [136]. Moreover, this 
study found that C-allele carriers have higher consumption of total fat, SFA, protein, 
carbohydrates and fructose than T-allele carriers [136]. However, one limitation of this gene-diet 
interaction is that it only applies to a small percentage of the population. In this case, the C-allele 
of the APOA2 SNP was found in only 10-15% of the participants. 
Another variant that shows significant gene-nutrient interactions is found in the FTO gene. A 
cross-sectional study examined 4839 subjects in the population-based Malmö Diet and Cancer 
study. It found that there was a strong association between the genetic variant FTO (rs9939609) 
and BMI only among those who reported high fat intake [137]. This association was replicated in 
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two US populations using the GOLD study and the Multi-Ethnic study of atherosclerosis 
(MESA), which highlighted that SFA intake modulates interactions between genetic variants and 
obesity [138]. Furthermore, numerous reports have shown that individual genetic variations 
interact with PUFA intake in modulating lipid metabolism. 
The Framingham Heart study found a gene-diet interaction exists between the APOA5-
1131T>C polymorphism, PUFA intake and blood lipids. This study identified that carriers of the 
1131C allele had higher TG levels when their consumption exceeded 6% of total energy intake 
[52]. In addition, it was previously shown that carriers of A-allele in the promoter region of the 
APOA1 gene (-75G/A SNP) exhibited higher HDL-C levels when they consumed high intakes of 
PUFA (approximately 40% of total energy intake) [139]. 
Another classic example of how gene-nutrient interactions affect blood lipid profiles was 
seen in the Canadian trial of dietary carbohydrate in Diabetes study. This study suggests that 
higher PUFA intake (8% of total energy intake) was positively associated with higher HDL 
levels [140]. The EPIC Norfolk cohort, which included data from ~23,000 individuals, similarly 
demonstrated that plasma LDL-C was positively related to SFA intake, with a particular degree 
of  risk associated with the E4 carriers of ApoE [141]. 
In addition to the above studies, intervention studies showed that modulating the PUFA/SFA 
ratio in the diet contributes to the genetic effects on blood lipids. An intervention trial found that 
carriers of the ApoE genotype exhibited a 10% increase in LDL-C after a DHA intervention 
(3.7g DHA/day) [142].  
The preceding studies evaluated dietary fat interactions with specific genes. Genes in the 
fatty acid desaturase (FADS) cluster have been studied extensively because they contribute to 
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PUFA concentrations in plasma. A GWAS of PUFA produced evidence of the association in the 
region of chromosome 11 that encodes FADS1, FADS2 and FADS3 [75]. 
2.5 Fatty acid desaturase (FADS) gene cluster 
The human fatty acid desaturase (FADS) gene cluster (which includes FADS1, FADS2 and 
FADS3) comprises 91.9 kb on chromosome 11q12-13. It has a head-to-head orientation of 
FADS1 and FADS2 and a tail-to-tail orientation of FADS2 and FADS3 [59]. Both genes are 
separated by an 11kb region, which suggests the possibility of a coordinated transcription of 
FADS1 and FADS2 [59]. 
FADS1 and FADS2 gene encode two desaturases: delta-5 desaturase (D5D) and delta-6 
desaturase (D6D), which are membrane-bound proteins [59]. The function of the protein product 
of the FADS3 gene is currently unknown. 
D5D and D6D are rate-limiting enzymes which are responsible for double bond formation in 
long-chain polyunsaturated fatty acids (PUFAs) [59]. D6D introduces a double bond between the 
pre-existing double bond and the carboxyl end of the fatty acid [59]. 
D6D catalyzes the conversion of linoleic acid (LA; C18:2n-6, ω-6) and α-linolenic acid 
(ALA; C18:3n-3) into γ-linolenic acid (GLA, C18:3n-6) and stearidonic acid (C18:4n-3), 
respectively. This is followed by an elongation step, after which D5D introduces a double bond 
at the Δ5 position in a 20-carbon fatty acid chain. D5D catalyzes the conversion of dihomo- γ-
linolenic acid (DGLA; C20:3n-6) and eicosatetraenoic acid (ETA; C20:4n-3) into arachidonic 
acid (AA, C20:4n-6) and eicosapentaenoic acid (EPA, C20:5n-3), respectively (Fig 1). The 
major downstream product of the omega-3 family is docosahexaenoic acid (DHA; C22:6n-3) 
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[59]. More particularly, EPA and DHA have numerous important functions in several biological 
processes [76].  
 
LA is the primary PUFA found in significant quantities in many vegetable oils (e.g, corn, 
safflower, soybean and sunflower oil) and in products made from such oils (e.g, margarines). 
The PUFA-rich oils are split into those with small amounts of ALA but high levels of LA, and 
those with high amounts of ALA. Flaxseed and canola are rich in ALA, whereas soy and walnut 
oil provide sufficient ALA as well as LA [143]. On the other hand, olive oil and avocado oils are 
oils rich in monosaturated fatty acids.  
In Mexico, the main sources of LA and ALA are chicken, eggs, corn tortillas, vegetable 
oils (e.i. corn, soy, sunflower, safflower or olive oil), and sweet breads in a high frequency of 
consumption per day [144]. Intakes of n-3 such as DHA, ALA and EPA are consumed from 
chicken, eggs, salmon, fresh fish, however their consumption is lower [144]. 
In a cross-sectional study in Mexicans aged 20-70years old was found that dietary 
patterns high in refined cereals, pastries, corn tortillas and sodas were associated with a 
significant increase in BMI [31] and dyslipidemia (low HDL-C and high TG) [32].  
It is well known that dietary fat is a mirror of the fatty acid composition in serum lipids, 
erythrocyte membranes and adipose tissue [145]. The activity of the delta-5 (D5D), delta-6 
(D6D) and elongase play an important role in several metabolic risk factors [146, 147]. 
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Fig 1. Fatty acid desaturases in PUFA biosynthesis. 
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Studies of substrate specificity and enzyme kinetics have identified that D5D has only two 
substrates, DGLA and ETA, while D6D has at least five substrates, such as LA, ALA, 
tetracosahexaenoic acid (C24:4n-6), tetracosapentaenoic acid (C24:5n-3), and palmitic acid 
(C16:0) [76]. The amount of substrates (LA and ALA) derived from the diet is equivalent to the 
fatty acid composition of the body [148, 149]. Moreover, changes in the type of dietary fat 
affects D5D and D6D activity in serum and skeletal muscles in human subjects [150].  
Thus, the activities of D5D and D6D are modulated by the diet [59, 70]. In this manner, high 
estimates of D6D activity and low estimates of D5D lead to greater production of AA, which is 
the precursor of chemical mediators of inflammation which play an important role in 
atherosclerosis and CVD [151]. 
Previous studies suggest that higher D6D activity is related to higher CVD mortality [152], 
insulin resistance [151] and obesity [147]. In contrast, higher D5D activity has been determined 
to be associated with decreased CVD mortality [152], and lower metabolic risk factors [146]. 
However, dietary intake influences the activities of desaturase enzymes, and genetic variants 
within FADS1 and FADS2 impact plasma PUFA concentrations [76, 153-155]. At present, 13 
SNPs have been identified as being associated with the AA/LA ratio [149, 156].  
Martinelli, et al., showed in a haplotype analysis that the carriers of an elevated number of 
risk alleles in the FADS gene cluster metabolized greater amounts of AA from dietary LA [149]. 
High plasma concentrations of AA may promote a proinflammatory response and is associated 
with a greater risk of myocardial infarction [156].  
Individual genetic variation in the FADS gene cluster has recently been extensively studied. 
FADS1-rs174546 in particular belongs to a highly preserved LD block. There are reports that 
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FADS1-rs174546 tags fifteen other SNPs in the Caucasian population [67]. Moreover, several 
studies have linked FADS1-rs174546 to PUFA concentration in plasma erythrocytes [67, 157, 
158]. In addition, carriers of the minor allele of FADS1-rs174546 have experienced significantly 
lower D5D activity. Therefore, subjects with the minor allele experienced lower AA 
concentrations independent of the diet [67]. 
Haplotype analysis has linked FADS polymorphism, particularly FADS-rs174546, with 
changes in serum cholesterol and triglycerides [33, 121, 159, 160]. Several studies of Europeans 
have shown that carriers of the minor alleles had lower levels of HDL-C, and higher levels of TG 
and LDL-C [33, 62, 63, 126]. Similar trends have been found in Caucasian, Chinese and 
Japanese adults (Appendix A).  
Similar trends in FADS SNPs and lipid profiles have been found among children in two 
independent studies which have shown that carriers of the minor allele of FADS1-rs174546 were 
associated with higher TG concentrations [161], and lower TC and HDL-C [61]. As regards 
HDL-C, the association between the minor allele of the FADS1-rs174546 and HDL-C become 
significant only among those with high intakes of n-3 PUFAS or ALA [4, 69]. However, gene-
nutrient interactions and individual genetic variations in the FADS gene cluster have not been 
described for young Mexicans. FADS1 SNPs are perfect candidates for studying CVD risk 
factors such as abnormal lipid profiles (lower HDL-C and higher LDL-C) that might increase the 
incidence of CVD later in life. Appendix B summarizes the main findings from gene-nutrient 
interaction studies conducted using European and Caucasian populations.  
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2.6 Environmental and genetic factors associated with dyslipidemia in Mexico 
Mexico has the world’s highest rate of obesity (32.8%), followed by the United States 
(31.8%) [162]. Obesity, age, and high TG are risk factors associated with early-onset diabetes 
and CVD in the Mexican population [10]. More particularly, there are reports that of an increase 
in the number of overweight and obese college students [13]. A cross-sectional study of a large 
representative sample of Mexican college students found that the prevalence of overweight and 
obese students increased from 12.1% to 26.7%, and from 13.2% to 37.3%, respectively, between 
1994 and 2008 [13].  
One major contributor to the increased rate of overweight and obese people in Mexico may 
be changes in dietary patterns. Since 1980, Mexicans have shifted their traditional diet towards 
more calorie-dense foods due to the commercial dominance of transnational food companies in 
the Mexican market [163, 164]. Flores, et al., state that the Mexican adult population exhibits 
three major dietary patterns; 1) a Western diet pattern that includes pastries, refined cereals, corn 
tortillas, and soft drinks; 2) 40% of the population consumes the traditional Mexican diet, which 
was 47.1% maize-based foods and refined foods, and 3) 20% of the population consumed a 
diverse diet (low consumption of maize and the high consumption of whole-fat dairy products, 
rice, pasta, meat, poultry, eggs, saturated fats, fruits and vegetables). Those who were classified 
as diverse consumed refined foods and sweets, habits associated with a higher BMI [165]. 
Diverse and refined diets are characterized by the high consumption of cholesterol, fats, and 
the low consumption of fiber [165]. Furthermore, this dietary pattern is associated with higher 
BMI, higher prevalence of metabolic syndrome, high serum TG, and low HDL-C [31, 32].  
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The most common dyslipidemia in the Mexican population is low HDL-C, followed by 
hypercholesterolemia [18]. Among the adult population 20 to 69 years of age, 60.5% had low 
HDL-C and 43.6% had hypercholesterolemia [18]. In addition, a large percentage of young 
Mexicans older than 20 years have also been affected by these lipid disorders; 61.9% had low 
HDL-C and 22.3% had hypertriglyceridemia [18].  
These metabolic abnormalities are associated with the Native American genetic heritage of 
the Mexican population [35].  
Polymorphisms in cholesterol transfer to and from HDL particles, and are associated with 
metabolic abnormalities in the Mexican population [35]. For instance, ATP-binding cassette 
transporter sub-family A member 1 (ABC-A1) is a protein responsible for transferring 
cholesterol and phospholipids across the cell membranes of peripheral tissues so they can be 
incorporated into HDL via ApoA1. It has been learned that 1 in 10 Mexican mestizos have a 
variant of ABCA1 (the R230C variant), which is associated with lower HDL levels. More 
specifically, this variant is common among Mayans, Purepechas, Yaquis, and Teenek, but is 
absent in European, African, South Asian, or Chinese populations [35]. 
ApoA1 is the major lipoprotein for HDL, and is responsible for accepting peripheral 
cholesterol that is passed along to the HDL particle from tissues and VLDL. The minor allele of 
the rs964184 APOA1/C3/A4/A5 gene cluster region is significantly more common among 
Mexicans (27%) than whites (12%), and this allele is strongly associated with triglycerides [37].  
In addition to this private mutation of the ABCA1 gene, a mutation in the LDL receptor and 
APOB gene has been found to exist exclusively among Mexicans [166, 167]. Thus, familial 
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combined hyperlipidemia (FCHL) is the most frequent primary dyslipidemia among Mexicans 
[2].  
Apolipoprotein B (ApoB) is found in chylomicrons and LDL, and high levels of ApoB are 
related to heart disease [168]. In the Mexican population, two polymorphisms were found in a 
case-control study to be associated with ApoB. The first polymorphism was localized near the 
ApoB messenger RNA editing enzyme (APOBEC1-rs1349411). This enzyme is important for 
the production of ApoB, which exists in two forms: ApoB-48, which is produced in the small 
intestine from ApoB-100, and is necessary for the assembly of chylomicrons, and ApoB-100 
which is synthesized in the liver and is found in VLDL, LDL-C and IDL particles. The second 
polymorphism was located in a highly consecutive noncoding region (rs142032) that was 
predicted to function as a regulatory element for serum ApoB [38].  
The FADS gene cluster is one of the loci that has recently been associated with plasma TG, 
HDL-C and LDL-C concentrations in populations that have European ancestry [33, 121]. The 
FADS gene is a promising candidate for studying gene-environment interactions because two of 
the key enzymes involved in the metabolism of PUFAs are encoded by the FADS gene. 
Moreover, SNPs for blood lipid levels in the FADS cluster gene have been less extensively 
studied in the Mexican population. 
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CHAPTER 3 
MATERIAL AND METHODS 
3.1 Study design 
San Luis Potosí is a centrally located state in Mexico and is the state capital. The 
overwhelming majority of applicants were from this city and surrounding areas. The 
Autonomous University of San Luis Potosi in Mexico (UASLP) routinely screens college 
applicants as part of their admission process. This pre-admission screening takes place from 
January to June. They screen about 10,000 students each year. 
In 2009, the UASLP and the University of Illinois began a multidisciplinary investigation on 
genetics, obesity and social-environment (UP AMIGOS project) during the pre-admission 
process of college age individuals. The UP AMIGOS project is a cross-sectional study that seeks 
to evaluate genetics, obesity, and social-environmental factors among young Mexican college 
students, ages 18-25 years who hail from the city of San Luis Potosí in Mexico. The protocol 
was reviewed and approved by the Institutional Review Board at UASLP and University of 
Illinois Champaign-Urbana. Informed consent was obtained from every participant. 
In brief, the UP AMIGOS project used a 309-item questionnaire [UP AMIGOS survey 
(Detección del estilo de vida, fenotipo y genotipo de riesgo para prevenir enfermedades crónico-
metabólicas: Diabetes Mellitus y Arteriosclerosis en adultos jóvenes de San Luis Potosí)] 
adapted for the Mexican population. This survey provided information about socio-economic 
status, family medical history, a food frequency questionnaire, physical activity and participant 
self-esteem. The UP AMIGOS survey was administered by trained interviewers in Spanish 
(Appendix C). The English translation can be also found here (Appendix D).  
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After the volunteers completed the UP AMIGOS survey, they were given health screenings 
at the university clinic following overnight fasts. The health screening consisted of: (1) 
anthropometric measurements, including height, weight, and blood pressure; (2) physician-
conducted medical interviews and physical exams, and (3) blood samples were draws to check 
blood biomarkers including fasting glucose and lipid profiles.  
The initial sample (n=854), a subset of individuals was selected for this project with a total of 
445 subjects were selected from the UP AMIGOS cohort for this nutrition-genetic study. More 
details about which participants were included and excluded participants can be found in 
Appendix E.  
3.2 Anthropometric and blood lipids measures  
Participants were barefoot and wore light clothing while their measurements were taken. 
Height was measured using a stadiometer and recorded to the nearest centimeter. Weight was 
measured using a calibrated scale and recorded to the nearest 0.01 kg. Body mass index (BMI) 
was calculated (BMI=kg/m
2
) and classified using the adult International Classification (WHO) as 
follows: underweight (≤18.49 kg/m2), normal weight (18.50-24.99 kg/m2), overweight (25.00-
29.99 kg/m
2), and obese (≥30.00 kg/m2).  
After an overnight fast, blood was drawn from the participants into EDTA-containing tubes 
by trained nurses at the Health Center at the UASLP. The blood samples were kept at 4°C and 
were separated within one hour of collection according to the SOP (standard operation 
procedure) previously established by the personal at UASLP. Aliquots were held at -80°C until 
laboratory testing. 
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Plasma lipid concentrations were determined in the Clinical Research Laboratory of the 
Chemistry School at UASLP on campus. TC was determined using enzymatic hydrolysis and 
oxidation. HDL-C was measured using a direct method, and serum TGs were determined 
according to the glycerol phosphate-oxidase peroxidase method, based on a colorimetric 
enzymatic reaction. Further details of these techniques can be found in the Appendix F. LDL-C, 
VLDL and non-HDL-C was calculated indirectly using a formula [169]. 
3.3 Measurement of dietary intake  
The 116-item food frequency questionnaire (FFQ) used in our study was developed by the 
National Institute of Public Health (INSP) in Mexico [170, 171], and has been widely used to 
collect dietary information from pre-school (< 5years of age) and school-age children (5-11 years 
of age), adolescents (12-19 years of age), adults (20-59 years of age) and older adults (60 – 99 
years of age) for both sexes [172].  
The National Institute of Public Health validated the FFQ by comparing it with a 24H recall 
[170]. The reproducibility was assessed twice during a one-year interval, and the validity was 
compared by the FFQ with samples obtained during a four-day 24H recall at three-month 
intervals [170].  
The correlation coefficients between the questionnaires and the mean values from the 24H 
recalls ranged from 0.4 or higher for total calories, carbohydrates, protein, total fat, and 
saturated, monosaturated, and polyunsaturated fatty acids intakes [170]. Parra, et al., validated 
this FFQ in order to evaluate dietary fatty acid intake by comparing the FFQ with the relative 
amounts of fatty acids in erythrocytes [173]. Estimates of fatty acid intakes obtained using this 
FFQ were moderately correlated using Pearson correlation coefficients among α-linolenic acids 
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(ALA: 0.32), docosahexaenoic acid (DHA: 0.35) and eicopentaenoic acid (EPA: 0.36). Each was 
significant at the p<0.05 level of significance for the composition of fatty acids from 
erythrocytes [173].  
The FFQ appears in the Procedure Handbook for Nutrition Projects [174] published by the 
National Institute of Public Health in Mexico [162]. The FFQ included 116 food items for adults 
and adolescents, and is organized into 12 “ad-hoc” selected food groups. The FFQ already has a 
section on the dietary sources of long chain n-3 fatty acids; fresh fish, sardines, tuna, seafood (an 
average of ½ cup containing shrimp, crab, shellfish and octopus), cod oil, fresh and canned 
salmon, and a small dry fish known as charales. In addition, the questionnaire had a section on 
oils so as to account for the n-6 fatty acids (including safflower oil, olive oil, soya oil and canola 
oil). It also had a section on other meat sources that contain arachidonic acid (AA), such as beef 
and pork, and a section on vegetable sources such green leaf products [174] (Appendix C and D). 
3.3.1 Calculation of nutrient intake  
Calculations were performed using SNUT 3.0 software (System of Nutritional Habits and 
Nutrient Intake), which was developed at the National Institute of Public Health (INSP), Mexico, 
and patented by the Ministry of Education, copyright Division in 1999 [173]. SNUT estimates 
the total amount of energy and nutrients found in each particular food and in the total diet 
consumed by each individual using a nutritional-composition database compiled by the INSP. It 
combines the USDA Food composition tables with other tables from Mexico and Latin America 
[175-177]. These tables include analytical information for over 300 foods consumed by the 
Mexican population [176-178].  
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Daily dietary nutrient intakes for study participants were estimated for each food. A nutrient 
score was calculated using the food nutrient content information in the food table, adjusted for 
the specific portion size in the questionnaire. This score was multiplied by the weight which 
corresponds to the frequency of use. The weights used were: 6 for reported frequencies of 6 or 
more times per day; 4.5 for 4-5 per day; 2.5 for 2-3 per day; 1 for 1 per day; 0.8 for 5-5 per 
week; 0.43 for 2-4 per week, 0.08 for 2-3 per month and 0.016 for 1 per month or less [170]. 
Only one answer per food item was allowed, and the survey accounted for seasonal 
availability [121].We calculated the number of grams per day of specific dietary fatty acids using 
the previously-mentioned weights.  
Total energy intake, total fat (TFA), saturated fat (SFA), monounsaturated fat (MUFA) and 
polyunsaturated fat (PUFA) were estimated using SNUT. This was reported as intake in terms of 
number of grams per day (g/day), and as percentage contribution to the total energy intake (%E). 
Dietary intake (g/day) of long-chain omega-3 PUFAs was calculated on the basis of the sum of 
20:5n3 (EPA), 22:6n3 (DHA) and 22:5n3 (DPA). Total omega-3 was calculated on the basis of 
the sum of 18:3n-3 (ALA) and long-chain omega-3. Total omega-6 was calculated on the basis 
of the sum of 20:4n6 (AA), 18:3n-6 (GLA) and 18:2n6 (LA) [172, 179]. The methodology for 
the analysis of dietary data from the Mexican National Health and Nutrition survey 2006 
indicates that dietary intakes which are more than 5 standard deviations away from the general 
distribution of energy, and less than 500 kcal, were excluded from this analysis [172].  
3.4 DNA extraction from whole blood 
Blood to be used for DNA extraction was collected in EDTA tubes, and DNA was extracted 
using a commercial DNA extraction procedure (Gentra Puregene Blood Kits, Quiagen, CA, 
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USA). Three volumes of RBC lysis buffer were added to 5ml of blood. The samples were 
centrifuged at 20,000g for 25 min. Most of the aqueous upper layer was discarded, leaving 
behind 1 ml which was used to prevent the loss of cells, and a brown pellet. The pellet was 
resuspended by adding 5 ml of cell lysis solution. Once the pellet was dissolved in the cell lysis, 
2 ml of protein precipitation solution was added to continue the extraction of DNA. The samples 
were then centrifuged at max speed (50,000g) for 20 min. After centrifugation, the aqueous layer 
was transferred into 50ml tubes containing 6 ml of isopropanol. All of the tubes were gently 
inverted several times, followed by centrifugation at 10,000g for 20 min. The supernatant was 
discarded and 10 ml of 70 % ethanol was added to wash the pellet. Once the pellet was 
resuspended, all of the tubes were centrifuged at 10,000g for 10 min. All of the tubes were air-
dried in a laminar air flow during 30-35 min. The dried pellet was rehydrated by adding 300-500 
μl DNA hydration solution buffer to a stock concentration of 50ng/ul (for small pellets ~250 μl, 
and big pellet ~450 μl) and were labeled and stored at −80°C. 
3.5 Single-nucleotide polymorphisms (SNPs) selection and genotyping 
HapMap-Mex database (Project SNP database used the NCBI B36 assembly-HapMap 
Genome Browser data release 28, phase II+III build 16, August 10) to select FADS SNPs. The 
tagger procedure in Haploview V4.2 was used to determine tag SNPs using a minor allele 
frequency ≥15% and pairwise tagging (r2 >0.8) in the FADS gene cluster in the Mexican 
population. Two SNPs, rs174546 (FADS1, position chr11:61569830) and rs1535 (FADS2, 
position chr11:61597972) were selected. FADS1-rs174546 and FADS2-rs1535 were in high 
linkage disequilibrium (LD) (r
2
 = 0.958; P < 0.001) with each other. Pairwise tagging revealed 
that rs1535 tags 5 (r
2
 = 0.88-0.95 for rs174556, rs174568, rs174549 and rs174555) in this LD 
block. In addition, the FADS1-rs174546 polymorphism has been described as interacting with 
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dietary PUFA intake and affecting plasma cholesterol concentrations in European adults and 
adolescents [4, 69]. Therefore, we decided to genotype both FADS SNPs in order to compare our 
associations with other populations. Detailed genotype determination methods were previously 
presented in Teran, et al. [174]. Appendix G is a global overview of the genotype frequencies 
and allele frequencies for different populations.  
The sequences of the primers and PCR conditions are shown in Appendix H. Genotyping 
was performed using fluoropolarization technology for selected SNPs in the FADS gene (those 
with minor allele frequencies –MAF- greater than 10%) (Appendix I). Fluorescent signals were 
read using the VICTOR5 Multi-label Plate Reader (Perkin Elmer Life Sciences, Massachusetts, 
USA).  
3.6 Statistical methods 
All of the analyses were performed using Statistical Analysis System software package 
version 9.3 (SAS Institute, Cary, NC, USA). Covariates were assessed for normality using the 
Shapiro Wilk’s test. Distributions of continuous variables were expressed in terms of adjusted 
means ± standard error (SE). Triglycerides (TG), and very-low-density liporprotein (VLDL) 
intakes of long-omega-3 and omega-6 were log-transformed for statistical testing.  
General linear models (GLM) assume that additive, recessive and dominant models of 
inheritance were used to investigate the association of the FADS1/FADS2 genotype with the 
lipid profile. Model 1 was adjusted for age and sex (basic analysis), and model 2 was adjusted 
thereafter for age, sex, and BMI, followed by Bonferroni correction in both cases.  
In order to study how gene-diet interactions determine blood lipid concentrations, we used 
multivariate linear regression models which included the main effects and interaction terms in a 
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model with dietary variables which were expressed in terms of grams per day adjusted for total 
calorie intake, as previously described by others [175]. However, we also tested our model using 
percentage of energy (%E) as a continuous or categorical variable. Dietary variables were also 
considered as categorical (tertiles based on the population distribution) and as continuous. 
Dietary intakes of omega-3 were classified in tertiles according to the omega-3-specific median 
%E (low: <0.06%E, medium: >0.06 and <0.16%E, and high: >0.16%E). The results are 
expressed as means ± standard error (S.E). All reported p-values for t-test were 2-tailed, and 
statistical significance was defined at the α = 0.05. 
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CHAPTER 4 
Genetic variations in the FADS gene cluster associated with blood lipid profile in young 
Mexican college students. 
ABSTRACT 
Introduction: Recent genome-wide association studies (GWA) of the Mexican population has 
identified several genetic loci associated with blood lipid levels in adults. The fatty acid 
desaturase (FADS) gene cluster in young Mexican college students has not been studied before. 
Objective: Our aim was to report on the SNP in the FADS gene cluster associated with lipid 
profiles in young Mexicans from the college-age UP AMIGOS cohort. Methods: 
Anthropometrics, cardiovascular disease history, and serum lipid profile were determined 
(n=445, aged 18-25 yrs.). Genotyping was conducted using the fluorescent polarization method. 
Genotype-phenotype associations were assessed using multiple linear regression models adjusted 
for sex, age and BMI. Results: Significant associations were found between carriers of the minor 
allele of FADS1/FADS2 genotypes and TC, LDL-C and non-HDL-C concentrations. In contrast, 
the association between the FADS1/FADS2 genotype and HDL-C, TG and VLDL were not 
significant. Conclusion: Our results suggest that FADS1/FADS2 genotypes were associated with 
TC, LDL-C and non-HDL-C concentrations starting at a young age. Moreover, these results 
replicate previous findings concerning European and Asian adult populations. Other factors such 
as diet should also be taken into consideration in order to better understand the onset of 
dyslipidemia among young Mexican college students. 
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4.1. INTRODUCTION 
Elevated low-density lipoprotein (LDL-C) cholesterol and low levels of high-density 
lipoprotein (HDL-C) cholesterol play an important role in the development of atherosclerosis and 
coronary heart disease [95, 168]. 
In Mexico, 65% of the adult population has low HDL-C, and 43.6% has 
hypercholesterolemia [18]. Similar trends have been found among young populations, where 
62% have low HDL-C and 22.3% have hypertriglyceridemia [18].  
A recent genome-wide association study in adults identified the genes which are associated 
with HDL-C and TG, and which contribute to the increasing predisposition toward dyslipidemia 
among Mexicans [1, 34, 37]. Furthermore, plasma lipid levels in childhood are known to be 
correlated with plasma levels in adulthood [182, 183].  
Several genome-wide association (GWAS) studies have consistently reported that the fatty 
acid desaturase (FADS) gene cluster is associated with lower total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C) and higher triglycerides (TG) [33, 40, 126, 159, 184, 185]. 
Several studies have identified that the minor alleles of SNPs in the FADS gene cluster are 
associated with higher total cholesterol and TG and lower HDL-C levels. Moreover, other 
studies have shown that the minor alleles affect the activity of the desaturases (D5D and D6D) 
changing the ratios between the desaturase substrates and their products [3, 143]. Thus, the 
present study investigated whether individual genetic variations of the FADS gene cluster were 
associated to blood lipid profiles in young Mexican adults. 
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4.2 RESULTS 
The clinical characteristics of the participants are exhibited in Table 2. No extreme values in 
the blood lipid profiles were found. Participant blood levels did not differ between males and 
females, except for weight, height and HDL-C concentrations.  
Table 2. Anthropometric measurements and blood lipid profiles for young Mexicans college 
students. 
Variables Males Females 
1
p-value 
N 219 208  
Age, yrs. 18.7 ± 1.2 18.8 ± 1.2 0.80 
Weight, kg 73.0 ± 15.4 61.0 ±12.6 <0.0001 
Height, m 1.7 ± 0.1 1.6 ± 0.1 <0.0001 
BMI, kg/m
2
 24.5 ± 4.5 23.7 ± 4.4 0.04 
TC, mg/dL 169.3 ± 32.6 173.7 ± 34.6 0.09 
HDL-C, mg/dL 46.8 ± 11.5 50.4 ± 11.8 0.0001 
TG, mg/dL
§
 104.7 ± 1.5 102.3 ± 1.5 0.31 
LDL-C, mg/dL 99.3 ± 26.7 99.6 ± 27.2 0.90 
VLDL, mg/dL
§
 20.9 ± 1.5 20.4 ± 1.5 0.31 
Non-HDL-C, mg/dL 122.5 ± 31.8 122.1 ± 31.2 0.85 
Values are presented as means ± standard deviation.  
§
Log-transformed values. 
1
p-values are adjusted by age and sex.  
Abbreviations: BMI: body mass index; TC: total cholesterol; TG: triglycerides; 
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein 
cholesterol; VLDL: Very-low-density lipoprotein. 
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4.2.1 Genetic distribution of selected SNPs 
Among the pool of study participants, 49% were homozygotic carriers for the major (MM) 
T-allele (TT), 44% were heterozygotic, and 7% were homozygotic carriers for the minor (mm) 
C-allele (CC) for FADS1-rs174546. The genotype and allele frequencies of the two SNPs 
included in the analysis are exhibited in Table 3. The FADS1-rs174546 was in the Hardy-
Weinberg equilibrium (HWE) with a minor allele frequency (MAF) of 0.29, and the FADS2-
rs1535 of 0.29. 
Table 3. Characteristics of the SNPs in the FADS gene cluster 
Genotype HapMap
1 
UP AMIGOS 
MEX 
SNP Gene Alleles CEU MEX-AM MM Mm mm 
MA
F HWE 
  
M/m MAF MAF 
n 
(%) 
n 
(%) 
n 
(%)  
 
rs174546 FADS1 T/C 0.23 0.45 
220 
(49%) 
193 
(44%) 
32 
(7%) 0.29 0.23 
rs1535 FADS2 G/A 0.34 0.34 
224 
(51%) 
190 
(43%) 
28 
(6%) 0.29 0.14 
1
HapMap 
CEU: Utah residents with Northern and Western European ancestry from the CEPH collection 
(n=113) 
MEX-AM: Mexican ancestry in Los Angeles, California (n=58). 
UP AMIGOS: Mexicans in San Luis Potosí, México. 
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4.2.2 Test for Hardy-Weinberg equilibrium 
The results of the LD analysis of rs174546 and rs1535 are illustrated in Fig 2. Analysis of the 
linkage disequilibrium (LD) block structure for the Mexican HapMap population revealed two 
LD blocks in the region of interest, with the most highly significant SNPs primary appearing in 
the first block (Fig 2). 
 
Fig 2. Linkage disequilibrium (LD) structure of SNPs near the FADS1/FADS2 locus in 
Mexicans. The HapMap Mex LD plot for the Mexican population is shown with the darkness of 
the shaded cells representing the degree of correlation between pairs of SNPs. *Marked SNPs 
were selected. The Scheme of the representation of LD follows the default setting of the 
Haploview Software. 
* * 
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4.2.3 Associations between the FADS1/FADS2 genotypes and blood lipids 
The results of the FADS SNPs associations’ analysis of blood lipid profiles are summarized 
for TC, LDL-C and non-HDL-C using graphical representations in Fig 3 and Fig 4. Additional 
information can be found in appendix J.  
A strong association was observed between FADS1/FADS2 SNPs and TC, LDL-C and non-
HDL-C levels (p-value <0.05). However, no associations were found between any FADS SNPs 
and HDL-C, TG and VLDL concentrations (Appendix J).  
In the dominant model, carriers of the C-allele of FADS1-rs174546 had significantly higher 
LDL-C and non-HDL-C (p<0.05) levels compared with those who are homozygous for the T 
allele (Fig 3 A, B, and C, respectively). A similar trend was found for carriers of the A-allele of 
FADS2-rs1535 compared with those homozygous of the G allele (Fig 4 A, B, and C, 
respectively). Thus, the C-allele of FADS1-rs174546 and the A-allele of FADS2-rs1535 might 
be considered to be risk alleles for higher levels of TC, LDL-C and non-HDL-C in the Mexican 
population. 
Furthermore, we observed a significant contribution of BMI on FADS1-rs174546 genotypes 
and the blood lipid profile. Carriers of the C-allele who were overweight or obese (OW/OB) had 
high blood concentrations comparable to carriers of the T-allele who were of normal weight 
(NW) (Fig 5, and Fig 6 for FADS1 and FADS2 genotypes, respectively). Thus, normal weight 
C-allele carriers had lower blood lipid levels than overweight/obese C-allele carriers. A similar 
trend was found among NW vs. OW/OB T-allele carriers. This highlights that being OW/OB 
might affect the protective effect of the T-allele for low levels of LDL-C. Additional information 
can be found in Appendix K  
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Fig 3. Association between FADS1-rs174546 genotypes and TC, LDL-C and non-HDL-C in 
Mexicans
1
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Values are means ± SE adjusted for sex, age and BMI, P-value (P<0.05) under the dominant model.  
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Fig 4. Association between FADS2-rs1535 genotypes and TC, LDL-C and non-HDL-C in 
Mexicans
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Fig 5. Association between FADS2-rs1535 genotypes and TC, LDL-C and non-HDL-C in 
Mexicans
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Fig 6. Association between FADS2-rs1535 genotypes and TC, LDL-C and non-HDL-C in 
Mexicans
1 
T
C
 (
m
g
/d
L
)
0
120
140
160
180
200
    
171.9 ± 2.8 184.3 ± 4.3 164.8 ± 2.8 177.0 ± 3.9 
AA + AG GG
L
D
L
-C
 (
m
g
/d
l)
0
60
80
100
120
140
    
99.0 ± 2.2 111.5 ± 3.4 92.2 ± 2.2 104.2 ± 3.0
AA + AG GG  
N
o
n
-H
D
L
-C
 (
m
g
/d
l)
0
80
100
120
140
160
    
118.2 ± 2.5 140.0 ± 3.8 112.3 ± 2.5 132.1 ± 3.5
AA + AG GG  
1
Values are means SE adjusted by sex, age and BMI, P-value (P<0.05) under the dominant 
model. NW: AA + AG (M/F: 67/86) vs. GG (M/F: 80/75); OW/OB: AA + AG (M/F: 41/34) 
vs. GG (M/F: 44/24). Values are significantly different between genotypes if they do not share 
the same letter (a, b, c or d; p<0.05).  
 
a 
b 
a,c 
a,b,d 
a 
b 
c 
a,b, d 
a 
b 
a,c 
b, d 
 45 
 
4.3 DISCUSSION 
Our study is the first to investigate the association between genetic variants of the FADS 
SNPs and blood lipid profiles in young Mexicans. Our results indicate that FADS1/FADS2 
genotypes tend to be associated with TC, LDL-C and non-HDL-C concentrations. Our results 
replicate previously published research on European populations that reported an association 
between the minor allele and blood cholesterol [63, 121].   
Minor alleles of FADS1/FADS2 SNPs were significantly associated with higher TC, LDL-C 
and non-HDL-C concentrations compared with carriers of the major alleles. What is remarkable 
is that FADS1 genotypes explained up to 8% of the variance in TC (R
2
=0.08, p=0.05), 10% of 
the variance in LDL-C (R
2
=0.10, p=0.01), and 15% of the variance in non-HDL-C (R
2
=0.15, 
p=0.03) in young Mexicans. Along these lines, Molto-Puigmarti, et al., found that FADS 
genotypes in children explained 2.4 – 2.9% of the variance in TC, and around 2% of the variance 
for HDL-C [61]. In addition, Standl, et al., found that, for 10-year old children, the FADS SNP 
explains 1.2% of the variance in LDL-C concentrations [186].  
A recent genome-wide association (GWA) study identified novel common variants 
associated with HDL-C, LDL-C and TG levels in children [187]. This study did not find any 
association between FADS SNPs and lipid profiles of youths. This study did highlight that 
different genes are expressed in childhood and adolescence compared with adulthood [187]. 
Other studies identified an association between FADS1-rs174546 and TG in adults [188, 189]. 
However, we were unable to replicate this association.  
In a larger hypertriglyceridemia cohort, there is a strong association between the FADS 
genotype and TG [188]. It is clear that in young Mexican adults the effects of FADS 
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polymorphisms on TC, LDL-C and non-HDL concentrations are strongest between 18-25 years 
old. 
Several limitations of our study should be addressed. First, no data was available regarding 
medications, smoking habits or alcohol consumption for our population. Second, we did not use 
random samples, which might have produced some form of bias. Further investigations which 
include controls for dyslipidemia are necessary in order to identify factors that directly influence 
blood lipid profiles. Moreover, longitudinal studies are needed to elucidate the genetic 
mechanism which underlies high LDL-C concentrations and their future consequences for this 
population. 
4.4 CONCLUSION 
In summary, the present study showed that FADS1-rs174546 and FADS2-rs1535 are 
associated with the plasma concentrations of TC, LDL-C and non-HDL-C in Mexican 
population. Most notably, we found that carriers of the minor allele of FADS1/FADS2 exhibited 
higher levels of atherogenic lipoproteins such as LDL-C. 
According to the NCEP (National Cholesterol Program), lipid management is essential for 
significantly reducing and preventing cardiovascular events [23, 24, 190, 191]. However, it is not 
presently known whether or not the FADS genotype has an impact on the development of CVD 
later in life. Nevertheless, these results indicate that young Mexican population need to engage in 
appropriate management of their serum blood lipids starting early in life, particular LDL-C 
levels, depending on their genetic predispositions in their FADS1/FADS2 genotypes. 
Furthermore, longitudinal studies are needed to identify the best strategy for future interventions. 
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CHAPTER 5 
Gene-nutrient variation in the FADS gene cluster associated with dietary fat intake profile 
on blood lipid profiles in young Mexican college students. 
ABSTRACT 
 
Introduction: Genetic variation in the FADS gene plays an important role modulating the 
association between dietary n-3 on plasma cholesterol concentrations in European population 
Objective: Our aim was to examine whether genetic variations in the FADS gene cluster interact 
with dietary intake of omega-3 and omega-6 to affect the lipid profiles. Methods: 
Anthropometrics, dietary intake, and serum lipid profile were determined (n=445, aged 18-25 
yrs.). Genotyping was conducted using the fluorescent polarization method. Genotype-phenotype 
associations were assessed by multiple linear regression models adjusted by sex, age, BMI, and 
calorie intake. Results: Significant associations between FADS1/FADS2 polymorphism and TC, 
LDL-C and non-HDL-cholesterol concentrations were observed. The minor C-allele of FADS1-
rs174546 and minor A-allele of FADS2-rs1535 were associated with higher TC and LDL-C. We 
observed significant association between FADS2-rs1535 and long-chain omega-3 intakes on TC 
(p=0.04), LDL-C (p=0.01) and non-HDL-cholesterol (p=0.03) concentrations. On the other hand, 
FADS1-rs17454 and long-omege-3 was only associated on LDL concentrations. In addition, 
significant interaction was observed between rs1535 and long-omega-3 on HDL-C (p-
interaction=0.03). Conclusion: Genetic variation in the FADS gene cluster potentially interacts 
with dietary intake of long-omega-3 to affect TC, LDL-C and non-HDL-C concentrations in the 
young Mexican population. Gene-nutrient interaction influencing blood lipid concentrations 
should be investigated further in other studies. 
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5.1 INTRODUCTION 
High rates of obesity, dyslipidemias and metabolic syndrome have been described in the 
Mexican population [10, 18, 192]. Recent studies indicate that a Western dietary pattern is the 
most common type of diet among young Mexicans. This diet has been linked to the widespread 
prevalence of obesity, metabolic syndrome and dyslipidemias recently reported in Mexico [31, 
32, 165, 193].  
Dietary intakes of ~250mg/d of docosahexanoic acid (DHA; C22:6 n-3) and eicosapentanoic 
acid (EPA; C20:5 n-3) have been reported to be associated with a reduced prevalence of 
metabolic syndrome [50], cardiovascular disease [111], and decrease serum TG and increased 
HDL-C [51]. These daily requirements might be the result of the consumption of two servings of 
seafood per week (4 oz. per serving) [194]. 
The FADS1 and FADS2 genes code for the delta-5 (D5D) and delta-6 desaturases (D6D).   
Both D5D and D6D are crucial enzymes responsible for the formation of long chain 
polyunsaturated fatty acids (PUFAs) [59]. Carriers of functional risk alleles in the FADS locus 
can form more AA from dietary LA, and may have greater susceptibility to atherosclerotic 
vascular damage [68, 77, 78, 195]. Moreover, dietary intake of omega-3 and omega-6 PUFAs 
modulates the association between the FADS gene variants and lipid levels in European children, 
adolescents and adults [64, 196, 197]. Given that Mexican adolescents obtain ~10% of their daily 
energy from PUFAs [30], the overall objective of the second aim is to test whether the dietary 
intake of omega-3 and omega-6 PUFAs modifies genetic associations in the FADS1-rs174546 
cluster gene and lipid profiles described above. 
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5.2 RESULTS 
The dietary fat intakes did not differ significantly between FADS1/FADS2 polymorphisms 
(Appendix L).  
Whatever the genetic model tested, there was no significant association between dietary fatty 
acid intake and the FADS1/FADS2 polymorphism in the lipid profiles, except for dietary intake 
of DHA, DPA, long-omega-3 and total-omega-3 (Appendix M).  
We found a significant association between the FADS1-rs174546 and FADS2-rs1535 
polymorphism and intake of long-omega-3 on LDL-C (p=0.005), as a continuous variables 
(Appendix M). On the other hand, we found borderline significant associations on TC (p=0.06) 
and non-HDL-C (p=0.05) between the FADS1/FADS2 genotypes and intake of long-omega-3 
(g/d) (Appendix M). In spite of this further adjustment, the intake of long-omega-3 did not 
substantially change the results observed between FADS1/FADS2 polymorphisms alone. 
There was a significant interaction between the FADS1-rs174546 polymorphism and long-
omega-3 (in g/d) on HDL-C concentrations (p-interaction=0.045) under the dominant model 
despite the lack of significant association between FADS1-rs174546 polymorphism and HDL-C 
concentrations in any model. No significant interactions were found between FADS2-rs1535 
polymorphism and the blood lipid profiles.  
After stratification by long-omega-3 intake in tertiles, there was still a significant association 
between FADS1-rs174546 and long-omega-3 tertiles (g/d) on LDL-C concentrations (p=0.03) 
(Fig. 7), but no interactions were found. Similar trend was found for FADS2-rs1535 (data not 
shown). No significant associations were found between the FADS1/FADS2 polymorphisms and 
intakes of omega-6 on blood cholesterol concentrations. 
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Fig 7. Association between FADS1-rs174546 and LDL-C concentrations in strata of long-
omega-3 intake in percent of energy (%E) in the UP AMIGOS cohort. 
 
 
 
 
 
 
 
 
Multiple linear regression model adjusted for sex, age, and BMI. P-value for trend across 
genotypes (p=0.03), long-omega-3 intake (p=0.01), and p-value of the interaction omega-
3*FADS1 (p=0.35). Dietary long-omega-3 intakes (%E) were classified in tertiles according to 
the study population distribution: Low <0.06%E, medium >0.06 to <0.16%E, and high 
>0.16%E.  
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5.3 DISCUSSION 
This study reports a significant association between the dietary intake of total omega-3 and 
the FADS1/FADS2 polymorphism on blood lipid concentrations in the Mexican population. Low 
intakes of omega-3 were associated with lower LDL-C concentrations in carriers of the C-allele. 
It is necessary to point out that in European populations for FADS1-rs174546, the minor T allele 
was associated with decreased LDL-C. By contrast, in the Mexican population, the C-allele was 
the minor allele and was associated with higher levels of LDL-C. This switch in the minor allele 
frequency has been described before as being a consequence of an adaptive evolution of the 
FADS gene cluster [198, 199]. Hence, our results replicate, the previously reported association 
between FADS1-rs174546 and LDL-C in European populations [4, 69], where carriers of the C-
allele with high intakes of n-3 PUFA intake were associated with higher LDL-C. However, the 
associations between omega-3 and FADS1-rs174546 on TC, HDL and non-HDL-C were not 
replicated. Thus, our data suggests that dietary intake of omega-3 modulates the impact of 
FADS1 genetic variants on LDL-C concentrations at a young age.  
Our results showed that higher omega-3 intakes were associated with higher LDL-C 
concentrations. This association has been described before by several intervention studies, where 
fish oil supplementation increased LDL-C and decreased TG concentrations [200]. However, the 
mechanism remains unclear. 
Previous studies have found that genetic variations in the FADs gene cluster influence the 
activity of the enzyme delta-5 desaturase (D5D) [67, 184, 201-203]. It appears from these studies 
that carriers of the minor allele exhibited significantly lower D5D activity than was the case for 
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subjects with the major allele [158, 201]. Furthermore, in haplotypes carrying the FADS1-
rs174546 minor allele has the largest effect affecting D5D activity [201]. 
D5D and deta-6 desaturase (D6D) are key enzymes in endogenous PUFA metabolism [59]. 
These enzymes are encoded by the FADS1 and FADS2 genes. Several studies have revealed that 
a defect in the activity of D5D and D6D might be a risk factor for the development of 
atherosclerosis [204], obesity [147, 205], diabetes [206] and dyslipidemia [63].  
Several studies reported associations between FADS SNPs and serum and erythrocyte fatty 
acids. These studies have shown that carriers of the minor allele of the FADS gene cluster had 
enhanced levels of LA, EDA, DGLA (n-6) and ALA (n-3), and decreased levels of GLA, AA, 
EPA and DHA [67, 155]. It is well known that arachidonic acid-derived eicosanoids produce 
primarily pro-inflammatory effects, whereas EPA-derived eicosanoids are less inflammatory 
[143]. Likewise, different studies suggest that dietary intakes of different PUFAs interact with 
FADS polymorphisms to affect blood lipid levels [4, 62]. In addition, the activity of D5D and 
D6D might be affected by diet [205].  
A cross-sectional study of two genetically similar Asian ethnic groups found that differences 
in lifestyle modifies the effect of FADS polymorphism on lipid profiles [62]. This study showed 
that in individuals with higher intakes of fish product, the risk allele of FADS1-rs174547 was 
associated with TG and HDL-C concentrations, whereas among individuals with higher intakes 
of livestock products and higher n-6/n-3 PUFAs ratios, the risk allele of FADS1-rs174547 was 
associated with decreased LDL-C but not with TG or HDL-C [62]. FADS1-rs174547 was in 
tight LD with FADS1-rs174546 in an Asian population. This study thus brings more information 
about the impact of lifestyle on FADS-lipid profiles, and highlights that individuals with risk 
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alleles in the FADS gene cluster may experience different responses to the dietary intake of 
PUFAs. 
Our study has several limitations. First, we investigated only one SNP in the FADS1-
rs174546 in high LD with FADS2-rs1535 in the FADS gene cluster. However, other genetic 
variants may be involved. Second, the nutrition survey used in this project was established by the 
Mexican National Institute of Public Health and published in the health and nutrition reports in 
2012 [172, 179]. Even when the nutritional survey shows that there is a high correlation between 
the questionnaire and serum and erythrocytes fatty acid levels in blood [144, 170, 173, 179]. 
There is no evidence (experimental) to indicate that the diet reflects the fatty acid composition in 
the body or the activity of the desaturases. Still, this is the first study to analyze dietary fatty 
acids in a genetic study, and future studies which include fatty acid composition in serum or 
erythrocytes may support our hypothesis. Third, we did not investigate the effect of other fatty 
acids, such as lauric acid (C12:0), myristic (C14:0) and palmitic acid (C16:0), all of which are 
quite prevalent in Western diets. This is important because a recent review showed that these 
fatty acids increase LDL-C concentrations [207].  
5.4 CONCLUSION 
In conclusion, genetic variations in the FADS1/FADS2 gene cluster were associated with the 
dietary intake of omega-3 on blood lipid concentrations in a young Mexican population. Further 
investigations are needed to explore the potential mechanism of the genetic variations in the 
FADS gene cluster in a dietary intervention, and to investigate how this association can be 
modified by physical activity, smoking or drinking habits in this age group. 
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CHAPTER 6 
CONCLUSIONS AND DIRECTIONS FOR FUTURE RESEARCH 
The Mexican population has a genetic predisposition towards dyslipidemias [1, 34, 37]. Our 
results show that FADS1-rs174546 and FADS2-rs1535 are associated with TC, LDL-C and non-
HDL-C levels in young Mexicans. These results replicate previous findings for European adult 
populations where FADS1-rs174546 was associated with TC and LDL-C [208]. On the other 
hand, we were unable to replicate the association between FADS SNP and HDL- and TG results 
reported to exist in children and adults [61, 189, 208].  
The most significant piece of evidence found in this research is the strong association 
between FADS SNPs and LDL-C concentrations in young Mexican populations. In addition, our 
study showed that FADS SNPs explain the high variability in blood lipid profiles in young 
Mexican adults. This is the most significant piece of evidence in this research because the age of 
our target population might be the key to identifying genes associated with cardiovascular risk 
profiles.  
Evidence from 2-year-old infants shows that FADS SNPs are associated with plasma TC and 
HDL-C concentrations [61]. This study shows that FADS polymorphisms explained 2.4 – 2.9% 
of the variance in TC, and around 2% of the variance for HDL-C [61]. In European children 
(~10yrs old), six FADS SNPs explain 1.2% of the variance for TC, HDL-C, LDL-C and TG 
concentrations [186]. In adolescents (~14yrs old), FADS SNPs have been associated exclusively 
with TC and non-HDL-C concentrations [69]. Finally, among people 60 years of age and older, 
FADS SNPs have been associated with higher risk of coronary artery disease [63, 78, 154, 209]. 
Thus, our study pointed out that ages 18 through 25 years may be the crucial period in life where 
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the development of atherosclerosis and consequently CVD is most heavily influenced by 
genetics. 
A longitudinal study supports our evidence drawn from a young adult population. Tikkanen, 
et al., found that lipid levels are strongly explained by the known lipid loci at young ages to a 
greater degree than in adults. This study showed that between 3 and 6 years of age, and again 
from 15 to 18 years of age, ~20% of the variance in HDL-C and TC can be explained by 
genetics, while among individuals between 33- to 45 years of age, the variance in blood lipids 
can be described only by ~10% [47]. Thus, among adults, intensive lifestyle interventions early 
in life might be the key to reducing the widespread prevalence of cardiometabolic risk factors. 
Cardiovascular disease (CVD) is the most common cause of death among Mexican adults 
[210]. LDL-C in particular is a strong predictor of CVD [211]. According to the ENSANUT 
2006, thirty percent of Mexican adults require lipid-lowering treatments [212]. 
Plasma accumulations of LDL-C are the result of defective LDL-C clearance [213]. This 
lipid metabolism disturbance is a genetic disorder described in familial hypercholesterolemia 
(FH) [213]. Along these lines, four mutations in the gene of the LDL receptor have been 
described in the Mexican population [167, 214]. Thus, screening for dyslipidemia among young 
Mexican population could be the best strategy for future interventions. Moreover, young 
Mexican adults have high SFA and TFA content in their diets [215], and this population requires 
interventions designed to improve their lipid profiles by reducing TFA in their diets. Other 
studies have shown that changes in the dietary fat intake, particularly TFA intake, were 
associated with a significant decrease in TC and LDL-C [216]. In addition, one strong factor 
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affecting the lipid profiles is obesity, and several studies have shown that in changes in the diets 
of obese individuals are less effective than is the case for lean individuals [216, 217].  
Several studies have identified the different genes that are significantly associated with status 
BMI that influences serum lipid profiles [218-223]. In the indigenous Mexican population, 8 
SNPs in 6 genes (ADIPOQ, FTO, TMEM18, INSIGN2, FAIM2/BCDIN3 and BDNF) were 
associated with increased BMI in children and adults [224].  
In the UP AMIGOS cohort the association of FTO-rs805704 with obesity and obesity-related 
phenotype was replicated [225]. Still, additional evidence is necessary in order to better 
understand the connection between the widespread prevalence of obesity and dyslipidemia in the 
Mexican population.  
This study found that BMI status has a strong impact on the FADS1/FADS2-lipid profile 
interaction. Moreover, our results highlight that dietary fat, particularly omega-3 intake, 
contributed to LDL-C concentrations. Thus, the benefit of the dietary intake of omega-3 on the 
blood lipid profile might depend on particular FADS genotypes.   
It is important to replicate these results using a well-powered cohort with good-quality 
dietary data and fatty acid composition in order to determine which factors (genetic or 
environmental) might contribute to the atherogenic phenotype. In addition, we learned from 
randomized trial studies that lifestyle interventions combined with physical activity result in 
significant weight losses and changes in cardiometabolic risk factors [226, 227]. Additional 
studies are clearly needed to determine the long-term effects of the interaction between genetics 
and diet on the blood lipid profiles in young adults later in life.  
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Appendix A 
Gene-phenotype studies with significant associations between FADS polymorphism and lipid concentrations. 
 SNPs Population Gene-phenotype interaction studies 
Aulchenko et al. 2009 rs174570 
17,797 – 22,562 European 
population cohort aged 18-104 
years old. 
Carriers of the major G allele had higher levels of TC and 
LDL-C than carriers of the minor A allele. 
Kathiresan et al. 2009 
rs174547 
19,840  Caucasian adults 
Carriers of the minor C allele had lower levels of HDL-C 
and higher levels of TG. 
Sabatti et al. 2009 
rs174537, rs102275, 
rs174546, rs174556 and 
rs1535 
4763 individuals from the 
Northern Finland Birth Cohort 
Carriers of the minor alleles had lower LDL-C levels. 
Nakayama et al. 2010 rs174547 
21,004 Japanese adults and 1,203 
Mongolian adults. 
In Japanese population carriers of C allele was associated 
with increased TG levels and decreased of HDL-C. In 
Mongolian population carriers of the C allele had 
decreased LDL-C. 
Liu et al. 2012 rs174546 30,500 Chinese adults 
Carriers of the minor C allele had higher TG, low HDL-C 
levels and increased coronary heart disease (CHD) risk.  
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Qin et al. 2011 rs174556 391 Chinese adults 
Carriers of the minor T allele were associated with higher 
prevalence of CHD.  
Merino et al. 2011 rs174547 
78 Caucasian adults and 69 Asian 
aged 20 -29 years  
Carriers of the C allele had lower desaturase activity than 
carriers of the T allele in both Caucasian and Asian. 
Martinelli et al. 2008 
rs174545, r174570, 
rs174583, rs1000778 
876 adults from European 
community. 
Carriers of the risk allele had higher desaturase activity 
associated with a higher pro-inflammatory response. 
Bokor et al. 2010  
rs174546, rs968567, 
rs174572, rs174611, 
rs174616, rs174602 
1,144 European adolescents 
Minor alleles of nine SNPs were associated with higher 
LA, AA and lower D5D activity.  
Tanaka et al. 2009 rs174537 1075 European adults 
Carriers of the minor T allele had lower concentration of 
AA, decreased LDL-C and TC compared to the carriers 
of the major allele. 
Sergeant et al. 2012  
rs174537, rs102275, 
rs174546, rs174556, 
rs1535, rs174576, 
rs174579 
166 European American (EA) and 
63 African American (AfA) 
adults. 
In EA seven SNPs in the FADS locus were strongly 
associated with AA, EPA and DGLA. Carriers of the T 
allele had lower AA levels and higher DGLA levels than 
carriers of the major allele. In AfA carriers of the G allele 
had higher AA levels. 
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Schaeffer et al. 2006 
rs174544, rs174553, 
rs174556, rs174561, 
rs174568, rs968567, 
rs99780, rs174570, 
rs2072114, rs174583, 
rs174589 
727 Caucasian adults from 
Germany 
SNPs in the FADS cluster were strongly associated with 
changes in phospholipids fatty acid composition. Carriers 
of the minor allele had increases levels of ALA and LA 
and decreased levels of AA. 
Malerba et al. 2008 
rs174545, rs174556, 
rs174561, rs3834458, 
rs174570, rs2224299, 
rs174583, rs174589, 
rs174611, rs174627 
658 Italian adults 
Minor alleles were associated to higher levels of LA, 
ALA, EPA and lower levels of AA in serum 
phospholipids and in erythrocyte cell membranes. 
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Appendix B 
Gene-phenotype-nutrient interaction studies with significant associations between FADS polymorphism on lipid concentrations 
Author 
SNPs 
Population 
Gene-phenotype 
interaction studies 
Gene-nutrient-phenotype 
interaction studies 
Hellstrand et al. 2012  
 
rs174547 
4,635 Swedish adult 
population 
Carrier of the C allele had 
lower LDL-C levels 
compared to those with the 
major allele. 
Carriers of the C-allele had lower 
LDL-C among individuals within 
the lowest tertile of long-chain ω-3 
PUFAS intake. 
Lu et al. 2010  
rs174546, rs482548, 
rs174570 
3575 subjects of the 
Doetichem Cohort 
Study (Netherlands). 
Carriers of the C allele had 
higher levels of TC, non-
HDL-C and HDL-C levels. 
In individuals consuming high 
intakes of ω-6 PUFAs had higher 
levels of TC. 
Mathias et al. 2011 
rs174537, rs174545, 
rs174546, rs174553, 
rs174556, rs174561, 
rs174568, rs99780 
224 individuals with 
European descent. 
 
Minor allele across all SNPs was 
consistently associated with 
decreased ω-6 PUFAs, and increased 
levels of DGLA. 
Al-Hilal et al. 2013 
rs174537 
310 Caucasian adults 
Minor allele was associated 
with decreased activities of 
Increasing EPA and DHA intake 
significantly decreased D5D and 
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D5D and D6D. decreased D6D activity. 
Dumont et al. 2011 rs174546 
573 European 
adolescents 
Carriers of the minor allele 
had decreased TC. 
Carriers of the minor T allele had 
decreased TC and non-HDL-C 
levels in adolescents reporting a 
high dietary ALA. 
Standl et al. 2012 
 
rs174545, rs174546, 
rs174556, rs174561, 
rs174575, 
rs3834458 
2006 European children 
aged 10 years old. 
Minor alleles were 
significantly associated with 
higher levels of TG and 
lower levels of TC, HDL-C 
and LDL-C levels. 
A higher ω-3 PUFA intake was 
associated with lower concentrations 
of TC, LDL-C, HDL-C and higher 
TG levels, independently of the 
genotype. 
Cormier et al. 2012  rs174546 254 Canadians aged 18-
50 years old. 
Carriers of the minor allele 
had higher TG than those 
with the major allele. 
Carriers of the C allele had higher 
TG levels, independently of ω-3 
PUFAS intake. 
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Appendix C 
UP AMIGOS survey- Spanish version 
 
CUESTIONARIO DE ALIMENTACION (FRECUENCIA DE CONSUMO). 
Adaptado del Instituto Nacional de Salud Pública. Centro de Investigación en Salud Pública. 
 
Por favor indique con una cruz en la columna que corresponda a la opción más cercana a su realidad y en la columna 
de la derecha registre el número correspondiente a la frecuencia de consumo reportada. 
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Productos lácteos 
NUNCA 
MENOS DE 
UNA VEZ AL 
MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
1 Un vaso de leche entera [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
2 
Una rebanada de queso fresco o ½ 
taza de queso cottage 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
3 Una rebanada de queso Oaxaca [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
4 
Una rebanada de queso Manchego o 
Chihuahua 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
5 Una cucharada de queso crema [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
6 Una taza de yogurt o búlgaros [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
7 Un barquillo helado de leche [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
 
Durante el año previo a este día ¿Con que frecuencia consumió usted FRUTAS? Por favor indique con una cruz, en la 
columna de frecuencias, la opción que considere más cercana a su realidad. Incluya las frutas que estuvieron 
disponibles solo en temporada. 
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Frutas 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
8 Un plátano [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
9 Una naranja [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
10 Un vaso con jugo de naranja o toronja [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
11 Una rebanada de melón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
12 Una manzana fresca [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
13 Una rebanada de sandia [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
14 Una rebanada de piña [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
15 Una rebanada de papaya [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
16 Una pera [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
17 Un mango [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
18 Una  mandarina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
19 Una porción de fresas (~10) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
20 Un durazno, chabacano o nectarina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
21 Una porción de uvas (de 10 a 15) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
22 Una tuna [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
23 Una porción de ciruelas (~6) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
24 Una rebanada de mamey [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
25 Un zapote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
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Durante el año previo a este día ¿Con que frecuencia consumió usted CARNES, HUEVO Y EMBUTIDOS? Por favor 
indique con una cruz, en la columna de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Carnes, huevo y embutidos 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
26 Un huevo de gallina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
27 Una pieza de pollo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
28 Una rebanada de jamón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
29 Un plato de carne de res [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
30 Un plato de carne de cerdo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
31 Una porción de atún [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
32 Un pedazo de chicharrón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
33 Una salchicha [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
34 Una rebanada de tocino [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
35 Un bistec de hígado o hígados de pollo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
36 Un trozo de chorizo o longaniza [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
37 Un plato de carne de pescado fresco 
(i.e. mojarra) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
38 Un plato de sardinas en tomate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
39 Media taza de mariscos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
40 Un plato de carnitas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
41 Un plato de barbacoa [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
 
Durante el año previo a este día ¿Con que frecuencia consumió usted VERDURAS? Por favor indique con una cruz, en 
la columna de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Verduras 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
42 Un jitomate en salsa o guisado [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
43 Un jitomate crudo o en ensalada [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
44 Una papa o camote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
45 Media taza de zanahoria [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
46 Una hoja de lechuga [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
47 
Media taza de espinacas u otra 
verdura de hoja verde (acelgas) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
48 Media taza de calabacitas o chayotes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
49 Media taza de nopalitos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
50 Una rebanada de tocino [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
51 Un plato de sopa crema de verduras [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
52 Medio aguacate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
53 Media taza de flor de calabaza [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
54 Media taza de coliflor [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
55 Media taza de ejotes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
56 
Una cucharadita de salsa picante o 
chiles con sus alimentos 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
57 Un platillo con chile seco [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
58 Un elote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
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Durante el año previo a este día ¿Con que frecuencia consumió usted LEGUMINOSAS o CEREALES? Por favor indique 
con una cruz, en la columna de frecuencias, la opción que considere más cercana a su realidad.  
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Leguminosas 
NUNCA MENOS DE 
UNA VEZ 
AL MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
59 Un plato de frijoles [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
60 Media taza de chicharos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
61 Un plato de habas verdes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
62 Un plato de habas secas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
63 Un plato de lentejas o garbanzos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
 
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Cereales 
NUNCA MENOS DE 
UNA VEZ 
AL MES 
VECES AL 
MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
64 Una tortilla de maíz [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
65 Una tortilla de trigo (tortilla de harina) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
66 Una rebanada de pan de caja (tipo Bimbo) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
67 Una rebanada de pan de caja integral [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
68 Un bolillo o telera [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
69 Una pieza de pan de dulce [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
70 Un plato de arroz [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
71 Un plato de sopa de pasta [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
72 Un plato de avena [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
73 
Un tazón de cereal de caja (tipo 
hojuelas de maíz) ¿Qué tipo?_______ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
74 Cereal alto en fibra ¿Cuál? _______ [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
 
Durante el año previo a este día ¿Con que frecuencia consumió usted GOLOSINAS o POSTRES? Por favor indique con 
una cruz, en la columna de frecuencias, la opción que considere más cercana a su realidad.  
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Golosinas o postres 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA SEMANA VECES Al DIA 
CLAVE 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
75 Una rebanada de pastel [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
76 
Una cucharadita de ate, miel, 
mermelada, cajeta o leche condensada 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
77 Una cucharadita de chocolate en polvo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
78 Una tablilla/barra de chocolate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
79 Una bolsa de frituras [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___][___] 
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Por favor, indique cualquier otro alimento que usted consumió al menos una vez por semana y que no encontró en 
los alimentos anteriores, además de la siguiente lista, al año previo a este día. Por favor indique con una cruz, en la 
columna de frecuencias, la opción que considere más cercana a su realidad.  
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Otros 
VECES A LA SEMANA VECES Al DIA CLAVE 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
 Charales secos [___] [___] [___] [___] [___] [___] [___] [___][___] 
 Aceite de hígado de bacalao [___] [___] [___] [___] [___] [___] [___] [___][___] 
 Salmon fresco [___] [___] [___] [___] [___] [___] [___] [___][___] 
 Salmon enlatado [___] [___] [___] [___] [___] [___] [___] [___][___] 
 Sardina en aceite [___] [___] [___] [___] [___] [___] [___] [___][___] 
  [___] [___] [___] [___] [___] [___] [___] [___][___] 
  [___] [___] [___] [___] [___] [___] [___] [___][___] 
  [___] [___] [___] [___] [___] [___] [___] [___][___] 
  [___] [___] [___] [___] [___] [___] [___] [___][___] 
 
OTRAS PREGUNTAS 
 CLAVE 
 ¿Cuántas cucharaditas de azúcar le agrega usted a su alimentos al o largo del día? 
Tome en cuenta lo que le pone al café, licuado, otras bebidas, etc. 
Cucharaditas [___][___] 
 ¿Le agrega usted sal a sus alimentos antes de probarlos? a) Si b) No [___] 
 ¿Se come usted el pellejo del pollo? a) Si b) No [___] 
 ¿Se come usted el “gordito” de la carne? a) Si b) No [___] 
  0 1-2 3-4 5-6 7-8 9-10 11-12  
 ¿Cuántos meses del año pasado consumió usted vitaminas? a b c d e f g [___] 
 ¿Cuál o cuáles? ________________________________________________________________________________ 
  0 1-2 3-4 5-6 7-8 9-10 11-12  
 ¿Cuántos meses del año pasado consumió usted suplemento de 
calcio? 
a b c d e f g 
[___] 
 ¿Cuál o cuáles? ________________________________________________________________________________ 
 ¿Considera usted que su alimentación ha cambiado durante el ultimo año? a) Si b) No [___] 
 Si ha cambiado ¿Por qué? 
____________________________________________________________________________________________ 
____________________________________________________________________________________________ 
_____________________________________________________________________________________________ 
 Observaciones 
_____________________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
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Appendix D 
UP AMIGOS survey- English version 
 
 
 
 
 
FOOD QUESTIONNAIRE –English version 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
HOW MANY 
EACH TIME? 1-3 1 2-4 5-6 1 2-3 4-5 6 
Dairy products (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
1. A glass of whole milk (%Fat____) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
2. A slice of cheese or  ½ cup cottage 
cheese(%Fat____) 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
3. A slice of Oaxaca cheese [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
4. A slice of Manchego cheese or Chihuahua 
cheese 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
A slice of fresh cheese [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
5. A spoonful of cream cheese [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
6. A cup of Yogurt or Bulgarians(%Fat____) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
7. A milk ice cream cone [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
 
 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY HOW 
MANY 
EACH 
TIME? 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Fruits (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
8. A banana [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
9. An Orange [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
10. A glass of orange juice or grapefruits [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
11. A slice of melon [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
12. A fresh apple [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
13. A slice of Watermelon [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
14. A slice of pineapple [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
15. A slice of papaya [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
16. A pear [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
17. A mango [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
18. A tangerine [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
19. One serving of strawberries (~10) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
20. A peach, apricot or nectarine [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
21. One serving of grapes (10 to 15) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
22. A prickly pear [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
23. A plum portion (~ 6) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
24. A slice of mamey sapote [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
25. A Zapote [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
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FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
HOW MANY 
EACH TIME? 1-3 1 2-4 5-6 1 2-3 4-5 6 
Meats, egg and sausage (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
26. A chicken egg [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
27. A piece of chicken [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
28. A slice of ham [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
29. A plate of beef meat [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
30.A plate of pork meat (carnitas) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
31. A portion of tuna fish [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
32. A piece of pork skin (dry) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
33. A sausage or frank [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
34. A slice of bacon [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
35. A liver steak or chicken livers [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
36. A piece of sausage or chorizo [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
37. A plate of fresh fish (i.e. perch) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
38. A plate of sardines in tomato [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
39. Half cup of seafood [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
40. Plate of shredded pork meat [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
41. A plate of Shredded beet meat-BBQ [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
A plate of Cooked Lamb [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
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FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS 
THAN 
ONCE A 
MONTH 
TIMES 
A 
MONTH 
TIMES A WEEK TIMES A DAY 
HOW 
MANY 
EACH 
TIME? 
METHOD OF COOKING 
1-3 1 2-4 5-6 1 2-3 4-5 6 
RAW 
(A) 
COOKED 
Vegetables (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
IN 
WATER 
(B) 
IN 
OIL 
(C) 
BAKED 
(D) 
42. A tomato in sauce or 
stew 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
43. A raw tomato or in a 
salad 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
44. A potato  [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
A Sweet Potato [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
45. Half a cup of carrot [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
46. A cup of lettuce [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
47. Half cup of spinach or 
other leafy green 
vegetables 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
48. Half cup of squash or 
chayote squash 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
49. Half cup of cactus [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
50. Canned hot green chili 
peppers 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
Dry hot chili pepper dish [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
51. A plate of cream 
vegetable soup 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
52. Half of a avocado [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
53. Half a cup of pumpkin 
flower/zucchini blossoms 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
54. Half a cup of cauliflower [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
55. Half a cup of green 
beans 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
56. A teaspoon of hot sauce 
or peppers with your food 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ [__] [__] [__] [__] 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Legumes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
59. A plate of beans [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
60. Half cup of peas [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
61. A plate of fava beans [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
62. A plate of dried fava beans [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
63. A dish of lentils or chickpeas [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
A plate of lima beans [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
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FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY HOW 
MANY 
EACH 
TIME? 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Cereals (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
64. A corn tortilla  [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
65. A flour tortilla [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
66. A slice of boxed white bread [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
67. A slice of boxed whole bread [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
68. A dinner or Kaiser roll [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
69. A piece of sweet bread [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
70. A plate of rice [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
71. A plate of pasta soup [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
72. A plate of oat [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
73. A bowl of cereal box (type of corn flakes). 
What kind?_________ 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
74. High-fiber cereal. Which?_______ [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY HOW 
MANY 
EACH 
TIME? 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Junk food or dessert (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
75. A piece of cake [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
A piece of Pastry (pie, donut, etc.) [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
76. A teaspoon of honey, jam, sweet-
condensed milk or caramel? 
[__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
77. A teaspoon of chocolate powder [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
78. A chocolate tablet/bar [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
79. A bag of chips [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
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FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Beverages (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
80. A medium size (can) cola drink [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
81. A flavored drink that has gas [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
82. A diet drink [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
83. A glass of sugared water [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
84. A cup of coffee without sugar [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
A cup of Instant coffee [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
85. A cup of “atole” without milk [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
86. A cup of “atole” with milk [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
87. A beer [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
88. A cup of table wine [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
89. A drink with rum, brandy or tequila [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] 
 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
HOW 
MANY/ 
MUCH 
EACH 
TIME? 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Oils and fats (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
90. Corn oil [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
91. Soy oil [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
92. Sunflower oil [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
93. Safflower oil [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
94. Olive oil [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
95. A teaspoon of margarine [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
96. A teaspoon of butter [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
97. A teaspoon of sour cream [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
98. A teaspoon of mayonnaise [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
99. A teaspoon of vegetable shortening [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
100. A teaspoon of animal fat [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
 
 
FREQUENCY OF CONSUMPTION 
FOOD NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
HOW 
MANY 
EACH 
TIME? 
1-3 1 2-4 5-6 1 2-3 4-5 6 
Cravings (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
101. A taco of pork [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
102. A sope or quesadilla [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
103. A plate of pozole [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
104. A tamal [__] [__] [__] [__] [__] [__] [__] [__] [__] [__] ____ 
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FREQUENCY OF CONSUMPTION 
FOOD 
TIMES A WEEK TIMES A DAY HOW 
MANY 
EACH 
TIME? 
1 2-4 5-6 1 2-3 4-5 6 
Others (1) (2) (3) (4) (5) (6) (7) 
Dry Fish, charales [__] [__] [__] [__] [__] [__] [__] ____ 
Cod liver oil [__] [__] [__] [__] [__] [__] [__] ____ 
Fresh salmon [__] [__] [__] [__] [__] [__] [__] ____ 
Canned salmon [__] [__] [__] [__] [__] [__] [__] ____ 
Sardines in Oil [__] [__] [__] [__] [__] [__] [__] ____ 
 [__] [__] [__] [__] [__] [__] [__] ____ 
 [__] [__] [__] [__] [__] [__] [__] ____ 
 [__] [__] [__] [__] [__] [__] [__] ____ 
 [__] [__] [__] [__] [__] [__] [__] ____ 
 
OTHER QUESTIONS 
 KEY 
How many teaspoons of sugar you add to your food, or during the day? Consider what you put on coffee, milk 
shakes, other drinks, etc. 
Teaspoon [__] [__] 
Do you add salt to your food before testing it? a) Yes b) No [__] 
Do you eat the skin of the chicken? a) Yes b) No [__] 
Do you eat the “fat” of the meat? a) Yes b) No [__] 
How many months last year did you consume vitamins? Which?___________________ 
0 1-2 3-4 5-6 7-8 9-10 11-12 
[__] 
a b c d e f g 
How many months last year did you consume a calcium supplement? 
Which?___________________ 
0 1-2 3-4 5-6 7-8 9-10 11-12 
[__] 
a b c d e f g 
Do you consider that you have changed your eating habits during last year? a) Yes b) No [__] 
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APPENDIX E 
Sample size and study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NOTE: Individuals with TG (>500mg/dL), HDL (>100mg/dl) and BMI > 40kg/m
2
 were 
excluded for this study. 
 
 
 
 
UP AMIGOS data 
n=854 
 
Dietary intake and blood 
lipids data 
n=710 
 
Declined 
n=130 
 
Calories criteria 
<500kcal, >7000kcal 
n=144 
 
n=130 
 Missing blood sample tubes* 
n=172 
Genetic database 
n=529 
 
Genetic database 
n=445 
Genotype efficiency  
FADS1 = 100% (n=445) 
FADS2 = 98% (n=442) 
 
n=130 
 
68
 
  20 
FADS gene-nutrient 
database 
FADS1= 427 
FADS2 = 424 
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APPENDIX F 
Principles for quantification of glucose and lipid profiles  
 
Chemistry of the Glucose measurement (GOD-PAP method)  
 
Glucose is determined after enzymatic oxidation in the presence of glucose oxidase (GOD) 
based on the following chemical reaction: 
 
                                                   Enzyme glucose oxidase (GOD) 
  Glucose + oxygen + water -------------------------------------------------> gluconolactona + H2O2 
 
Enzyme peroxidase      
 2H2O2  + 4-aminofenazona + fenol ------------------------------> colored complex + 4H2O2 
 
The intensity of the colored complex is directly proportional to the glucose concentration in 
the sample, and conversion factor of mg/dL x 0.0555 = mmol/L was used. 
 
Chemistry of the CHOD-PAP method of cholesterol measurement.  
 
The cholesterol is determined after enzymatic hydrolysis and oxidation based on the 
following chemical reaction:  
Cholesterol esterase 
Cholesterol ester + H2O ------------------------------> Cholesterol + Fatty acids 
                                                         Cholesterol oxidase 
                     Cholesterol + O2 --------------------------------------->Cholestene-3-one + H2O2 
                                                                Peroxidase  
2H2O2 + phenol + 4-Aminoantipyrine -------------------> quinoneimine (colored complex) + 4H2O  
 
The indicator quinoneimine (colored complex) is formed from hydrogen peroxide and 4-
aminoantipyrine in the presence of phenol and peroxidase. The intensity of the colored complex 
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is directly proportional to the total cholesterol concentration in the sample, and a conversion 
factor of mg/dL x 0.0259 = mmol/L was used. 
 
Chemistry of the GOP-PAP method of triglycerides measurement  
 
Triglycerides are generally determined by a combination of hydrolysis to glycerol and free 
fatty acids and measurement of the amount of glycerol released based on the following chemical 
reaction: 
  Lipoprotein Lipase 
            Triglycerides + 3H20-------------------------------> glycerol + 3Fatty acids 
      
     Enzyme glycerol kinase 
Glycerol + ATP---------------------------------> glycerol-3-phosphate + ADP 
 
                          Glycerol  
              Phosphate oxidase (GPO) 
Glycerol-3-phosphate + O2 ------------------------------------> Dihydroxyacetone phosphate + H2O2 
 
     Peroxidase 
2H2O2 + 4-aminoantipyrine (4-AAP) + 4-Chlorophenol-------------> Colored complex + 4 H2O2  
 
 
The intensity of the colored complex is directly proportional to the triglycerides 
concentration in the sample, and a conversion factor of mg/dL x 0.0113 = mmol/L was used. 
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Chemistry of the HDL measurement  
 
The method used in the present procedure is based on the following reactions.  
Step 1 
                 Cholesterol esterase (CE) 
               CM + VLDL + LDL-C esters --------------------------------> Cholesterol + fatty acids  
 
 
                                                            Cholesterol Oxidase (CO) 
            Cholesterol esters + O2  -------------------------------------> Δ4-Cholesterone + H2O2 
                                                                                     
      Catalase 
2 H2O2 --------------------> 2 H2O2+ O2 
Step 2 
                                                                  Cholesterol esterase (CE) 
                   HDL-Cholesterol esters + O2  ---------------------------------> Cholesterol + fatty acids 
                                                             
                                                             Cholesterol Oxidase (CO) 
                   Cholesterol esters + O2  -------------------------------------> Δ4-Cholesterone + H2O2      
             
                 Peroxidase 
2 H2O2 + 4-aminoantipyrine + HDAOS+ H+ + H2O ---------------> Colored complex + 5H2O 
 
HDAOS= (N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline 
 
The intensity of the colored complex is directly proportional to HDL-cholesterol 
concentration in the sample, and a conversion factor of mg/dL x 0.0259 = mmol/L was used. 
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Appendix G 
FADS genotype and frequency distribution among population 
Table G.1. FADS1 genotype and frequency distribution among population 
. 
 
 
 
Population 
FADS1-rs174546                                     Genotype frequencies 
genotype freq count genotype freq Count genotype freq count Total 
ASW (A) C/C 0.84 48 C/T 0.16 9 T/T 0 0 57 
CEU (C) C/C 0.44 50 C/T 0.43 49 T/T 0.12 14 113 
CHB (H) C/C 0.40 55 C/T 0.45 61 T/T 0.15 21 137 
CHD (D) C/C 0.28 31 C/T 0.42 46 T/T 0.30 32 109 
GIH (G) C/C 0.82 83 C/T 0.18 18 T/T 0 0 101 
JPT (J) C/C 0.47 53 C/T 0.43 48 T/T 0.11 12 113 
LWK (L) C/C 0.96 106 C/T 0.04 4 T/T 0 0 110 
MEX (M) C/C 0.14 8 C/T 0.43 25 T/T 0.43 25 58 
MKK (K) C/C 0.87 135 C/T 0.13 20 T/T 0.01 1 156 
TSI (T) C/C 0.59 60 C/T 0.33 34 T/T 0.08 8 102 
YRI (Y) C/C 0.98 144 C/T 0.02 3 T/T 0 0 147 
           
Population 
Allele frequencies 
   Ref-allele Other-allele 
 
   allele freq count allele freq Count Total 
   ASW (A) C 0.92 105 T 0.08 9 114 
   CEU (C) C 0.66 149 T 0.34 77 226 
   CHB (H) C 0.62 171 T 0.38 103 274 
   CHD (D) C 0.50 108 T 0.50 110 218 
   GIH (G) C 0.91 184 T 0.09 18 202 
   JPT (J) C 0.68 154 T 0.32 72 226 
   LWK (L) C 0.98 216 T 0.02 4 220 
   MEX (M) C 0.35 41 T 0.65 75 116 
   MKK (K) C 0.93 290 T 0.07 22 312 
   TSI (T) C 0.76 154 T 0.25 50 204 
   YRI (Y) C 0.99 291 T 0.01 3 294 
   Note: the 'reference' allele is the base observed in the reference genome sequence at this location 
   
73
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Table G.2 FADS2 genotype and frequency distribution among population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Population 
FADS2 -rs1535                                       Genotype frequencies 
genotype freq count genotype freq count genotype freq count Total 
ASW (A) A/A 0.77 44 A/G 0.21 12 G/G 0.020 1 57 
CEU (C) A/A 0.44 50 A/G 0.43 49 G/G 0.12 14 113 
CHB (H) A/A 0.40 55 A/G 0.45 61 G/G 0.15 21 137 
CHD (D) A/A 0.29 31 A/G 0.44 47 G/G 0.28 30 108 
GIH (G) A/A 0.82 83 A/G 0.18 18 G/G 0 0 101 
JPT (J) A/A 0.46 52 A/G 0.43 49 G/G 0.11 12 113 
LWK (L) A/A 0.85 93 A/G 0.15 16 G/G 0.01 1 110 
MEX (M) A/A 0.14 8 A/G 0.41 24 G/G 0.45 26 58 
MKK (K) A/A 0.69 107 A/G 0.30 46 G/G 0.02 3 156 
TSI (T) A/A 0.57 58 A/G 0.34 35 G/G 0.09 9 102 
YRI (Y) A/A 0.78 115 A/G 0.21 31 G/G 0.01 1 147 
Population 
Allele frequencies 
Ref-allele Other-allele 
 
allele freq count allele freq count Total 
ASW (A) A 0.88 100 G 0.12 14 114 
CEU (C) A 0.66 149 G 0.34 77 226 
CHB (H) A 0.62 171 G 0.38 103 274 
CHD (D) A 0.50 109 G 0.50 107 216 
GIH (G) A 0.91 184 G 0.09 18 202 
JPT (J) A 0.68 153 G 0.32 73 226 
LWK (L) A 0.92 202 G 0.08 18 220 
MEX (M) A 0.35 40 G 0.66 76 116 
MKK (K) A 0.83 260 G 0.17 52 312 
TSI (T) A 0.74 151 G 0.26 53 204 
YRI (Y) A 0.89 261 G 0.11 33 294 
Note: the 'reference' allele is the base observed in the reference genome sequence at this location 
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Appendix G (cont.) 
 
Population descriptors: 
ASW (A): African ancestry in Southwest USA 
CEU (C): Utah residents with Northern and Western European ancestry from the CEPH 
CHB (H): Han Chinese in Beijing, China. 
CHD (D): Chinese in Metropolitan Denver, Colorado 
GIH (G): Guajarati Indians in Houston, Texas. 
JPT (J): Japanese in Tokyo, Japan. 
LWK (L): Luhya in Webeye, Kenya. 
MEX (M): Mexican ancestry in Los Angeles, California. 
MKK (K): Maasai in Kinyawa, Kenya 
TSI (T): Tuscan in Italy 
YRI (Y): Yoruban in Ibadan, Nigeria
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Appendix H 
PCR conditions 
Primers design 
SNPs  Sequence 
FADS1   
rs174546 F ACCCCCTCTGAGTATTAAACTAT 
 R AGATGGAAGAAGGCCTTAAC 
FADS2   
rs1535 F GACCTTTCTGGTTAATTACCCAT 
 R ACCAGATTTATAGTCCATGAAAGT 
 
Polymerase Chain Reaction (PCR) Gradient 
1. PCR Master Mix 
QIAGEN Mix (3.5mM MgCl2) Final Conc. Per reaction (µl) 
Qiagen PCR buffer (10X, 15mM MgCl2) 1X 1 
MgCl2(25mM) 3.5mM total 0.8 
dNTPs (5mM each) 100µM each 0.4 
F-primer (10µM)    120nM 0.12 
R-primer (10µM)    120nM 0.12 
Taq (5U/µl)  0.04 
dH2O µl  2.52 
Total µl  5 
 
QIAGEN Mix (1.5mM MgCl2) Final Conc. Per reaction (µl) 
Qiagen PCR buffer (10X, 15mM MgCl2) 1X 1 
MgCl2(25mM) 3.5mM total 0.0 
dNTPs (5mM each) 100µM each 0.4 
F-primer (10µM)    120nM 0.12 
R-primer (10µM)    120nM 0.12 
Taq (5U/µl)  0.04 
dH2O µl  3.32 
Total µl  5 
   
2. Add 5µl of each mix and 5µl of genomic DNA @1ng/ µl (5ng DNA/rxn).  
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3. PCR (Start program & wait until block is ~80˚C before adding tubes to machine) 
                        95ºC                     2 min 
   35                 95ºC                    30 sec 
 cycles             61.5ºC                 30 sec   
                        72ºC                  1.5 min 
                        Repeat 34 cycles 
                        72ºC                     5 min 
             Hold 4ºC  
Agarose gel (1.5%) preparation 
1.  Set up the gel tray with comb.  
2. Mix 0.75g agarose with 50ml of 1x TAE buffer.  
3. Microwave this mixture for 30 second intervals until the agarose is dissolved..  
4. Allow the mixture to cool until it can be handled. 
5. Add 3 µl of Ethidium Bromide to the mixture. 
5. Pour the solution into the gel tray and allow it to solidify (approximately 20-30min). 
6.  Prepare and load the DNA, for every 5 µl of a DNA sample add 5 µl of the master mix 
described before.   
7. Run the gel for 35 min at a constant of 100 volts 
8. Take a picture and save your data 
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PCR Conditions 
SNPs MgCl2 Temperature 
FADS1 rs174546 3.5mM 62ºC 
FADS2 rs1535 3.5mM 60ºC 
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Appendix I 
Fluoropolarization Method (FP) 
Prepare a 396 Black plates samples with 5 µl of dry DNA at 1ng/µl.  
1. Master Mix 
QIAGEN Mix (3.5mM MgCl2) Per reaction (µl) 410 reactions(µl) 
Qiagen PCR buffer (10X, 15mM MgCl2) 0.6 264 
MgCl2(25mM) 0.48 196.8 
dNTPs (2.5mM each) 0.24 98.4 
F-primer (10µM) 0.072 29.5 
R-primer (10µM) 0.072 29.5 
Taq (5U/µl) 0.024 9.84 
dH2O µl 4.512 1850 
Total µl 6 2460 
     
Select the PCR conditions according to the SNPs 
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2. SAP. 
 Per reaction (µl) 410 reactions (µl) 
ExoSAPit µl 0.65 266.5 
dH2O µl 4.35 1783.5 
Total µl 5 2050 
     Select FPSAP 
3. Single Base Pair Extension for primers  
 Per reaction (µl) 410 reactions(µl) 
Single Base Extension buffer 2 820 
Primer (P3 or P4) 0.5 205 
Terminator mix 0.5 205 
Thermosequenase 0.025 10.3 
dH2O µl 6.975 2860 
Total µl 10 4100 
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APPENDIX J 
Supplementary tables for chapter 4 
Table J.1 FADS1-rs174546 and blood lipid profiles. 
FADS1 (rs174546)
 
Variable 
 
CC 
(n=28) 
CT 
(n=187) 
TT 
(n=212) 
CC + CT 
(n=215) 
1
p 
2
p 
 
3
p 
 
TC 166.3±6.3 177.0±2.4 169.2±2.3 175.5±2.3 0.04 0.29 0.05 
HDL-C 49.6±2.2 49.4±0.9 49.6±0.8 49.4±0.8 0.98 0.85 0.88 
TG
 §
 92.9±6.9 101.2±2.9 104.2±47.8 100.0±2.5 0.32 0.23 0.27 
LDL-C 96.4±4.9 103.7±1.9 96.3±1.8 102.7±1.8 0.01 0.48 0.01 
VLDL
§
 18.6±1.4 20.2±0.6 20.8±0.5 20.0±0.5 0.32 0.23 0.28 
Non-HDL-C 116.5±5.5 126.1±2.2 119.1±2.0 124.9±2.0 0.04 0.32 0.04 
 
All variables are adjusted means (mg/dL) ± standard error. 
§
Log-transformed values 
1
Additive model (CC vs CT vs TT), 
2
Recessive model (CC vs CT+TT) and 
3
Dominant (CC+CT 
vs TT) were adjusted by sex, age, age
2
, age
3
 and BMI. 
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APPENDIX J (cont.) 
Supplementary tables for chapter 4 
Table J.2 FADS2-rs1535 and blood lipid profiles. 
 
FADS2 (rs1535)  
 
Variable 
AA 
(n=24) 
GA 
(n=186) 
GG 
(n=214) 
AA + AG 
(n=210) 
1
p 
2
p 
3
p 
TC 166.3±6.8 176.9±2.4 168.8±2.8 175.7±2.3 0.04 0.34 0.04 
HDL-C  48.8 ±2.4   49.5±0.9   49.4±0.8   49.4±0.8 0.96 0.63 0.98 
TG
§
 90.8 ±7.4 101.9±2.8 103.5±2.6 100.5±2.5 0.31 0.18 0.44 
LDL-C  97.8 ±5.3 103.5±1.9   96.1±1.8 102.8±1.8 0.02 0.70 0.01 
VLDL
§
  18.2 ±1.5   20.4±0.6   20.7±0.5   20.1±0.5 0.31 0.18 0.44 
Non-HDL-C 117.2 ±6.0 126.0±2.2 118.9±2.0 125.0±2.0 0.04 0.42 0.04 
 
All variables are adjusted means (mg/dL) ± standard error. 
§ 
Log-transformed values. 
1
Additive model (AA vs GA vs GG),
 2
Recessive model (AA vs AG+GG), and 
3
Dominant model 
(AA+AG vs GG) were adjusted by sex, age, age
2
, age
3
 and BMI.
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APPENDIX K 
Supplementary tables for chapter 4 
Table K.1 FADS1-rs174546 and the lipid profiles in the UP AMIGOS cohort by BMI 
categories
1
. 
FADS1 (rs174546)
 
 CC + CT                     TT
 
N (M/F) 
NW 
(66,83) 
OW/OB 
(40,35) 
NW 
(81,81) 
OW/OB 
(45,23) 
1
p-
value 
TC, mg/dL 171.8 ± 2.7 183.8 ± 4.2 165.2 ± 2.8 177.4 ± 3.9 0.06 
HDL-C, mg/dL   51.2 ± 0.9  45.5 ± 1.5   52.1 ± 1.0   44.7 ± 1.4 0.99 
TG, mg/dL
§
 90.8 ± 2.9 124.5 ± 6.0 94.0 ± 3.2 128.8 ± 5.9 0.40 
LDL-C, mg/dL   99.2 ± 2.1 110.8 ± 3.4   92.1 ± 2.2 104.8 ± 3.0 0.01 
VLDL, mg/dL
§
   18.2 ± 0.5  24.9 ± 1.2   18.8 ± 0.6   25.8 ± 1.2 0.40 
Non-HDL-C, mg/dL 118.4 ± 2.4 139.2 ± 3.8 112.3 ± 2.5 132.8 ± 3.5 0.04 
 
All variables are adjusted means ± standard error. 
§ 
Log-transformed values.  
1
Dominant model (CC+CT vs TT) was adjusted by sex, age, and BMI. 
Abbreviations: M: males; F; females; NW; normal weight; OW: overweight; and OB: obese. 
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APPENDIX K (cont.) 
Supplementary tables for chapter 4 
Table K.2. FADS2-rs1535 and the lipid profiles in the UP AMIGOS cohort by BMI categories
1
. 
FADS2 (rs1535)
 
 AA + AG                    GG
 
N (M/F) 
NW 
(67,86) 
OW/OB 
(41,34) 
NW 
(80,75) 
OW/OB 
(44,24) 
1
p-
value 
TC, mg/dL 171.9 ± 2.8 184.3 ± 4.3 164.8 ± 2.8 177.0 ± 3.9 0.04 
HDL-C, mg/dL  51.3 ± 1.0   45.3 ± 1.5   51.7 ± 1.0   44.9 ± 1.4 0.99 
TG, mg/dL
§
 91.0 ± 2.9 125.3 ± 6.1 93.1± 3.0 104.0 ± 4.8 0.60 
LDL-C, mg/dL   99.0 ± 2.2 111.5 ± 3.4   92.2± 2.2 104.2 ± 3.0 0.01 
VLDL, mg/dL
§
   18.2 ± 0.6   25.1 ± 1.2   18.6 ± 0.6   25.6 ± 1.2 0.60 
Non-HDL-C, mg/dL 118.2 ± 2.5 140.0 ± 3.8 112.3 ± 2.5 132.1 ± 3.5 0.03 
 
All variables are adjusted means ± standard error. 
§ 
Log-transformed values.  
1
Dominant model (AA + AG vs GG) was adjusted by sex, age, and BMI. 
Abbreviations: M: males; F; females; NW; normal weight; OW: overweight; and OB: obese. 
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APPENDIX L 
Supplementary tables for chapter 5 
Table L.1 Dietary intake by genotypes of rs174546 in FADS gene cluster region. 
 
CC 
(n=32) 
CT 
(n=193) 
TT 
(n=220) 
CC + CT 
(n=225) 
Additive 
model 
p-value 
Dominant 
model 
p-value 
TFA, g/d 92.1 ± 3.7 89.5 ± 1.5 88.1 ± 1.4 89.9 ± 1.4 0.53
1
 0.35
1
 
SFA, g/d 30.4 ± 1.4 27.5 ± 0.6 28.0 ± 0.5 27.9 ± 0.5 0.14
1
 0.91
1
 
MUFA, g/d 36.3 ± 1.6 33.9 ± 0.7 34.0 ± 0.6 34.2 ± 0.6 0.38
1
 0.77
1
 
Omega 3, g/d§ 0.31 ± 0.1 0.22 ± 0.0 0.21 ± 0.0 0.20 ± 0.0 0.08
1
 0.23
1
 
Omega 6, g/d§ 8.8 ± 0.6 8.5 ± 0.2 8.4 ± 0.3 8.5 ± 0.2 0.79
1
 0.68
1
 
Omega 6/3r 12.1 ± 0.7 11.8 ± 0.3 12.4 ± 0.3 11.8 ± 0.3 0.38
2
 0.18
2
 
TFA, %E 37.1 ± 1.4 36.8 ± 0.6 35.5 ± 0.5 36.9 ± 0.5 0.16
2
 0.06
2
 
SFA, %E 12.2 ± 0.5 11.4 ± 0.2 11.2 ± 0.2 11.5 ± 0.3 0.18
2
 0.21
2
 
MUFA, %E 14.7 ± 0.6 14.0 ± 0.3 13.6 ± 0.2 14.1 ± 0.2 0.19
2
 0.12
2
 
Omega 3, %E§ 0.13 ± 0.0 0.10 ± 0.0 0.9 ± 0.0 0.10 ± 0.0 0.10
2
 0.23
2
 
Omega 6, %E§ 3.9 ± 0.3 3.8 ± 0.1 3.7 ± 0.1 3.8 ± 0.0 0.72
2
 0.53
2
 
Data are expressed as means ± standard error. §Log-transformed values. 
1
Model adjusted by sex, 
age, age
2
, age
3
, body mass index (BMI) and total energy intake. 
2
Model adjusted by sex, age, 
age
2
, age
3
 and BMI. Abbreviations: TFA, SFA, MUFA, Omega 3: EPA, DPA and DHA, Omega 
6: LA, GLA, and AA. Omega-6/Omega-3 ratio. 
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Table L.2 Dietary intake by genotypes of rs1535 in FADS gene cluster region. 
 
AA 
(n=28) 
GA 
(n=190) 
GG 
(n=224) 
AA + AG 
(n=218) 
Additive 
model 
p-value 
Dominant 
model 
p-value 
TFA, g/d 93.0 ± 3.9 89.3 ± 1.5 88.5 ± 1.4 89.8 ± 1.4 0.54
1
 0.51
1
 
SFA, g/d 30.2 ± 1.5 27.6 ± 0.6 28.1 ± 0.5 27.9 ± 0.5 0.22
1
 0.80
1
 
MUFA, g/d 36.2 ± 1.8 33.8 ± 0.7 34.1 ± 0.6 34.1 ± 0.6 0.46
1
 0.96
1
 
Omega 3, g/d§ 0.30 ± 0.1 0.20 ± 0.0 0.20 ± 0.0 0.20 ± 0.1 0.05
1
 0.26
1
 
Omega 6, g/d§ 9.2 ± 0.7 8.4 ± 0.3 8.4 ± 0.2 8.5 ± 0.1 0.53
1
 0.73
1
 
Omega 6/3 r 12.1 ± 0.8 11.8 ± 0.3 12.4 ± 0.3 11.8 ± 0.3 0.30
1
 0.13
1
 
TFA, %E 37.4 ± 1.4 36.7 ± 0.6 36.5 ± 0.5 36.8 ± 0.5 0.19
2
 0.08
2
 
SFA, %E 12.0 ± 0.5 11.5 ± 0.2 11.2 ± 0.2 11.5 ± 0.2 0.34
2
 0.26
2
 
MUFA, %E 14.5 ± 0.7 14.0 ± 0.3 13.6 ± 0.2 14.0 ± 0.2 0.29
2
 0.16
2
 
Omega 3, %E§ 0.14 ± 0.0 0.10 ± 0.0 0.09 ± 0.0 0.1 ± 0.0 0.07
2
 0.23
2
 
Omega 6, %E§ 4.1 ± 0.3 3.8 ± 0.1 3.7 ± 0.1 3.8 ± 0.0 0.44
2
 0.48
2
 
 
Data are expressed as means ± standard error. §Log-transformed values. 
1
Model adjusted by sex, 
age, age
2
, age
3
, body mass index (BMI) and total energy intake. 
2
Model adjusted by sex, age, 
age
2
, age
3
 and BMI. Abbreviations: TFA, SFA, MUFA, Omega 3: EPA, DPA and DHA, Omega 
6: LA, GLA, and AA. Omega-6/Omega-3 ratio. 
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APPENDIX M 
Supplementary tables for chapter 5 
FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.046 0.95 0.01 167.6± 6.4 176.5 ± 2.5 169.4 ± 2.3 
HDL-C, mg/dL 0.029 0.92 0.98 49.2 ± 2.3 49.6 ± 0.9 49.4 ± 0.8 
TG, mg/dL
§
 0.037 0.01 0.42 2.0 ± 0.034 2.0 ± 0.013 2.0 ± 0.01 
LDL-C, mg/dL 0.051 0.66 0.045 97.6 ± 5.0 103.2 ± 2.0 96.5 ± 1.8 
VLDL, mg/dL
§
 0.037 0.01 0.42 1.28 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.046 0.56 0.14 118.5 ± 5.9 125.4 ± 2.3 119 ± 2.1 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.048 0.88 0.06 167.3 ± 7.0 176.6 ± 2.5 169.0 ± 2.3 
HDL-C, mg/dL 0.027 0.88 0.92 48.7 ± 2.5 49.6 ± 0.9 49.3 ± 0.8 
TG, mg/dL
§
 0.038 0.007 0.47 1.97 ± 0.04 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.050 0.74 0.04 98.7 ± 5.5 103.1 ± 2.0 96.3 ± 1.8 
VLDL, mg/dL
§
 0.038 0.007 0.47 1.27 ± 0.038 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.048 0.48 0.11 118.6 ± 6.4 125.5 ± 2.3 119.1 ± 2.1 
All variables are adjusted means ± standard error. 
§
Log-transformed values.
1
Models were adjusted for 
sex, age, age
2
, age
3
, total energy intake and total fat intake (TFA). 
2
P-values for differences in lipid 
concentrations with assumption of an additive genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.043 0.91 0.07 175.3 ± 2.3 169.4 ± 2.3 
HDL-C, mg/dL 0.029 0.93 0.93 49.5 ± 0.8 49.4 ± 0.8 
TG, mg/dL
§
 0.037 0.009 0.22 1.99 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.048 0.69 0.02 102.4 ± 1.8 96.5 ± 1.8 
VLDL, mg/dL
§
 0.037 0.009 0.22 1.29 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.044 0.53 0.09 124.5 ± 2.1 119 ± 2.1 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.044 0.84 0.046 175.6 ± 2.3 169.0 ± 2.3 
HDL-C, mg/dL 0.027 0.89 0.86 49.5 ± 0.84 49.3 ± 0.8 
TG, mg/dL
§
 0.037 0.006 0.39 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.050 0.77 0.02 102.6 ± 1.87 96.3 ± 1.8 
VLDL, mg/dL
§
 0.037 0.006 0.39 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.046 0.45 0.06 124.7 ± 2.2 119.1 ± 2.1 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, total energy intake and total fat intake (TFA).  
2
P-values for differences in lipid concentrations with assumption of a dominant genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.08 0.83 0.04 166.5 ± 6.33 176.9 ± 2.4 169.1 ± 2.3 
HDL-C, mg/dL 0.10 0.73 0.98 49.7 ± 2.2 49.4 ± 0.85 49.6 ± 0.8 
TG, mg/dL
§
 0.17 0.002 0.38 1.98 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.84 0.02 96.5 ± 5.0 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.17 0.002 0.38 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.36 0.04 116.8± 5.5 126.± 2.8 119.0 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 
0.085 0.76 0.04 166.6 ± 6.9 176.9 ± 2.5 169.0 ±  2.3 
HDL-C, mg/dL 
0.097 0.69 0.98 49.0 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 
0.178 0.001 0.37 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.10 0.93 0.02 98.1 ± 5.4 103.4 ± 2.0 96.1± 1.8 
VLDL, mg/dL
§
 
0.177 0.001 0.37 1.26 ± 0.034 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 
0.153 0.29 0.04 117.6 ± 6.0 126.0 ± 2.2 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and total fat intake 
(TFA). 
2
P-values for differences in lipid concentrations with assumption of an additive genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.79 0.048 175.6 ± 2.28 169.1 ± 2.29 
HDL-C, mg/dL 0.099 0.73 0.89 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.17 0.002 0.32 2.0 ± 0.01 2.01 ± 0.01 
LDL-C, mg/dL 0.099 0.87 0.011 102.7 ± 1.8 96.3 ± 1.78 
VLDL, mg/dL
§
 0.17 0.002 0.32 1.3 ± 0.012 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.15 0.33 0.04 124.9 ± 2.02 119.0 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
TFA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 
0.08 0.72 0.033 175.77 ± 2.3 168.8 ± 2.3 
HDL-C, mg/dL 
0.097 0.69 0.97 49.44 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 
0.17 0.001 0.48 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 
0.10 0.96 0.009 102.8 ± 1.8 96.1 ± 1.77 
VLDL, mg/dL
§
 
0.17 0.001 0.48 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 
0.15 0.27 0.032 125.0 ± 2.05 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and total fat intake 
(TFA). 
2
P-values for differences in lipid concentrations with assumption of a dominant genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
SFA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.08 0.32 0.05 166.9 ±  6.34 176.8 ± 2.4 169.2 ± 2.3 
HDL-C, mg/dL 0.099 0.99 0.98 49.7 ± 2.2 49.4 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.18 0.0004 0.38 1.98 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.97 0.02 96.5 ± 5.0 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.18 0.0004 0.38 1.28 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.18 0.04 117.2± 5.6 126.0.± 2.2 119.1 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
SFA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.087 0.30 0.04 166.9 ± 6.9 176.8 ± 2.5 169.0 ±  2.3 
HDL-C, mg/dL 0.097 0.98 0.98 49.0 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 0.182 0.0005 0.38 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.91 0.02 98.1 ± 5.3 103.4 ± 2.0 96.1± 1.8 
VLDL, mg/dL
§
 0.18 0.0005 0.38 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.155 0.17 0.05 117.9 ± 6.0 126.0 ± 2.2 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and saturated fat intake 
(SFA). 
2
P-values for differences in lipid concentrations with assumption of an additive genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
SFA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.26 0.05 175.5 ± 2.28 169.2 ± 2.29 
HDL-C, mg/dL 0.099 0.99 0.90 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.18 0.0003 0.24 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.099 0.87 0.011 102.7 ± 1.8 96.3 ± 1.78 
VLDL, mg/dL
§
 0.18 0.0003 0.24 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.15 0.14 0.04 124.8 ± 2.02 119.1 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
SFA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.08 0.26 0.036 175.7 ± 2.3 168.8 ± 2.3 
HDL-C, mg/dL 0.097 0.99 0.96 49.45 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 0.18 0.0003 0.39 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 0.10 0.86 0.009 102.8 ± 1.8 96.1 ± 1.77 
VLDL, mg/dL
§
 0.18 0.0003 0.39 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.15 0.14 0.036 125.0 ± 2.05 118.9 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and saturated fat intake 
(SFA). 
2
P-values for differences in lipid concentrations with assumption of a dominant genetic 
model 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
MUFA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.09 0.29 0.05 166.8 ± 6.3 176.9 ± 2.4 169.1 ± 2.3 
HDL-C, mg/dL 0.10 0.26 0.98 49.6 ± 2.2 49.4 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.18 0.0005 0.38 1.98 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.72 0.01 96.7 ± 5.0 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.18 0.0005 0.38 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.14 0.04 117.1± 5.5 126.1.± 2.2 119.0 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
MUFA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.088 0.22 0.04 166.9 ± 6.9 176.9 ± 2.4 169.0 ±  2.3 
HDL-C, mg/dL 0.099 0.23 0.98 49.0 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 0.18 0.0002 0.36 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.58 0.02 98.2 ± 5.3 103.4 ± 2.0 96.1± 1.8 
VLDL, mg/dL
§
 0.18 0.0002 0.37 1.26 ± 0.03 1.30 ± 0.0 1.32 ± 0.0 
Non-HDL-C, mg/dL 0.157 0.91 0.05 117.8 ± 6.0 126.0 ± 2.2 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and monounsaturated fat 
intake (MUFA). 
2
P-values for differences in lipid concentrations with assumption of an additive 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
MUFA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.25 0.048 175.6 ± 2.28 169.1 ± 2.29 
HDL-C, mg/dL 0.102 0.26 0.89 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.18 0.0004 0.27 2.0 ± 0.01 2.01 ± 0.01 
LDL-C, mg/dL 0.10 0.66 0.011 102.8 ± 1.8 96.2 ± 1.78 
VLDL, mg/dL
§
 0.18 0.0004 0.27 1.3 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.12 0.04 124.9 ± 2.02 119.0 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
MUFA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.08 0.19 0.034 175.74 ± 2.3 168.8 ± 2.3 
HDL-C, mg/dL 0.099 0.23 0.97 49.44 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 0.18 0.0002 0.42 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 0.10 0.55 0.009 102.8 ± 1.8 96.1 ± 1.77 
VLDL, mg/dL
§
 0.18 0.0002 0.42 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.15 0.08 0.033 125.0 ± 2.05 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and monounsaturated fat 
intake (MUFA). 
2
P-values for differences in lipid concentrations with assumption of a dominant 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
PUFA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.08 0.99 0.04 166.4 ± 6.3 176.9 ± 2.4 169.2 ± 2.3 
HDL-C, mg/dL 0.10 0.57 0.98 49.7 ± 2.2 49.3 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.17 0.018 0.31 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.73 0.01 96.5 ± 54.9 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.17 0.02 0.31 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.33 0.03 116.5± 5.5 126.2 ± 2.2 119.0 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
PUFA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.09 0.93 0.04 166.5 ± 6.9 176.9 ± 2.5 169.0 ±  2.3 
HDL-C, mg/dL 0.10 0.57 0.98 49.1 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 0.17 0.01 0.29 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.64 0.02 98.1 ± 5.3 103.5 ± 1.9 96.1± 1.8 
VLDL, mg/dL
§
 0.17 0.01 0.29 1.26 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.27 0.04 117.3 ± 6.0 126.0 ± 2.2 118.8 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and polyunsaturated fat 
intake (PUFA). 
2
P-values for differences in lipid concentrations with assumption of an additive 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
PUFA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.95 0.05 175.6 ± 2.28 169.2 ± 2.29 
HDL-C, mg/dL 0.10 0.58 0.88 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.16 0.02 0.32 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.099 0.75 0.01 102.8 ± 1.8 96.3 ± 1.78 
VLDL, mg/dL
§
 0.16 0.02 0.32 1.3 ± 0.01 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.15 0.35 0.04 124.9 ± 2.02 119.0 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
PUFA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.08 0.94 0.034 175.7 ± 2.3 168.8 ± 2.3 
HDL-C, mg/dL 0.097 0.57 0.98 49.43 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 0.17 0.01 0.48 2.0 ± 0.012 2.01 ± 0.01 
LDL-C, mg/dL 0.10 0.65 0.008 102.8 ± 1.8 96.1 ± 1.8 
VLDL, mg/dL
§
 0.17 0.01 0.48 1.30 ± 0.012 1.32± 0.01 
Non-HDL-C, mg/dL 0.15 0.27 0.03 125.0 ± 2.05 118.9 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and polyunsaturated fat 
acid intake (PUFA). 
2
P-values for differences in lipid concentrations with assumption of a 
dominant genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
ALA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.09 0.23 0.05 166.4 ± 6.3 176.8 ± 2.4 169.3 ± 2.3 
HDL-C, mg/dL 0.099 0.81 0.98 49.7 ± 2.2 49.4 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.16 0.69 0.31 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.66 0.02 96.6 ± 4.9 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.16 0.69 0.31 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.58 0.04 116.6 ± 5.5 126.0.± 2.2 119.1 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
ALA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.088 0.23 0.05 166.3 ± 6.9 176.8 ± 2.5 169.0 ± 2.3 
HDL-C, mg/dL 0.097 0.79 0.98 49.0 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 0.16 0.71 0.29 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.68 0.02 98.1 ± 5.3 103.4 ± 2.0 96.1± 1.8 
VLDL, mg/dL
§
 0.16 0.71 0.29 1.26 ± 0.03 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.60 0.05 117.2 ± 6.0 126.0 ± 2.2 118.9 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and alpha-linoleic acid 
(ALA). 
2
P-values for differences in lipid concentrations with assumption of an additive genetic 
model. 
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FADS1-rs174546
1
  Means ± SE 
 
R
2
 
p-value 
ALA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.22 0.06 175.4 ± 2.28 169.3 ± 2.29 
HDL-C, mg/dL 0.099 0.81 0.89 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.15 0.67 0.26 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.64 0.01 102.7 ± 1.8 96.3 ± 1.78 
VLDL, mg/dL
§
 0.15 0.67 0.26 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.15 0.56 0.05 124.8 ± 2.03 119.1 ± 2.02 
 
FADS2-rs1535
1
  Means ± SE 
 R
2
 
p-value 
ALA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.08 0.23 0.04 175.6 ± 2.3 168.9 ± 2.3 
HDL-C, mg/dL 0.097 0.79 0.98 49.43 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 0.15 0.71 0.42 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 0.10 0.68 0.009 102.8 ± 1.8 96.1 ± 1.77 
VLDL, mg/dL
§
 0.15 0.71 0.42 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.15 0.60 0.038 125.0 ± 2.06 118.9 ± 2.0 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and alpha-linoleic acid 
(ALA). 
2
P-values for differences in lipid concentrations with assumption of dominant genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
LA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.09 0.13 0.04 166.2 ±  6.3 176.9 ± 2.4 169.2 ± 2.3 
HDL-C, mg/dL 0.099 0.97 0.98 49.7 ± 2.2 49.4 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.16 0.81 0.31 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.13 0.01 96.4 ± 5.0 103.7 ± 1.9 96.3 ± 1.8 
VLDL, mg/dL
§
 0.16 0.81 0.31 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.19 0.03 116.4 ± 5.5 126.1 ± 2.2 119.1 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
LA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.089 0.15 0.03 166.1 ± 6.9 177.0 ± 2.4 168.8 ±  2.3 
HDL-C, mg/dL 0.097 0.94 0.98 49.0 ± 2.4 49.5 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 0.16 0.74 0.30 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.15 0.02 97.8 ± 5.3 103.5 ± 1.9 96.1 ± 1.8 
VLDL, mg/dL
§
 0.16 0.74 0.30 1.26 ± 0.03 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.155 0.22 0.04 117.0 ± 6.0 126.0 ± 2.2 118.9 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and linoleic acid (LA). 
2
P-values for differences in lipid concentrations with assumption of an additive genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
LA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.08 0.14 0.05 175.5 ± 2.3 169.2 ± 2.3 
HDL-C, mg/dL 0.099 0.97 0.90 49.4 ± 0.8 49.56 ± 0.8 
TG, mg/dL
§
 0.15 0.79 0.28 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.13 0.011 102.7 ± 1.8 96.3 ± 1.8 
VLDL, mg/dL
§
 0.15 0.79 0.28 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.15 0.19 0.04 124.8 ± 2.0 119.1 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
LA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.08 0.16 0.035 175.7 ± 2.3 168.8 ± 2.3 
HDL-C, mg/dL 0.097 0.94 0.96 49.45 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 0.15 0.69 0.44 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 0.10 0.16 0.009 102.8 ± 1.8 96.1 ± 1.77 
VLDL, mg/dL
§
 0.15 0.69 0.44 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.15 0.25 0.035 125.0 ± 2.05 118.9 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and linolenic acid (LA). 
2
P-values for differences in lipid concentrations with assumption of dominant genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-
value 
ARA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.08 0.85 0.05 166.5 ±  6.3 177.0 ± 2.5 169.6 ± 2.3 
HDL-C, mg/dL 0.098 0.85 0.88 49.6 ± 2.2 49.1 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 0.16 0.15 0.36 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.10 0.47 0.02 96.7 ± 4.9 103.9 ± 1.9 96.6 ± 1.8 
VLDL, mg/dL
§
 0.16 0.15 0.36 1.27 ± 0.03 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.15 0.95 0.04 116.8 ± 5.6 126.5.± 2.2 119.4 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-
value 
ARA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 
0.084 0.81 0.04 166.6 ± 6.9 177.2 ± 2.5 169.3 ±  2.3 
HDL-C, mg/dL 
0.096 0.83 0.94 49.0 ± 2.4 49.2 ± 0.86 49.5 ± 0.8 
TG, mg/dL
§
 
0.16 0.16 0.34 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.10 0.45 0.02 98.2 ± 5.3 103.9±1.95 96.5 ± 1.8 
VLDL, mg/dL
§
 
0.16 0.16 0.34 1.26 ± 0.03 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 
0.15 0.99 0.04 117.5 ± 6.0 126.5 ± 2.2 119.2± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and arachidonic acid 
(ARA). 
2
P-values for differences in lipid concentrations with assumption of an additive genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
ARA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 
0.08 0.84 0.06 175.6 ± 2.3 169.6 ± 2.32 
HDL-C, mg/dL 
0.098 0.84 0.66 49.1 ± 0.8 49.6 ± 0.8 
TG, mg/dL
§
 
0.16 0.15 0.37 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.10 0.46 0.014 102.9 ± 1.8 96.6 ± 1.79 
VLDL, mg/dL
§
 
0.16 0.15 0.37 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 
0.15 0.96 0.04 125.2 ± 2.05 119.4 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
ARA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 
0.08 0.84 0.04 176.0 ± 2.3 169.3 ± 2.3 
HDL-C, mg/dL 
0.096 0.83 0.74 49.2 ± 0.81 49.5 ± 0.8 
TG, mg/dL
§
 
0.16 0.15 0.59 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 
0.10 0.46 0.009 103.2 ± 1.8 96.5 ± 1.78 
VLDL, mg/dL
§
 
0.16 0.15 0.59 1.30 ± 0.012 1.31 ± 0.012 
Non-HDL-C, mg/dL 
0.15 0.97 0.03 125.5 ± 2.07 119.2± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and arachidonic acid 
(ARA). 
2
P-values for differences in lipid concentrations with assumption of dominant genetic 
model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
EPA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 0.11 0.68 0.16 170.2 ± 6.8 178.1 ± 2.6 171.5 ± 2.5 
HDL-C, mg/dL 0.10 0.52 0.98 50.3 ± 2.3 49.8 ± 0.91 49.9 ± 0.9 
TG, mg/dL
§
 0.16 0.55 0.40 1.99 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.12 0.22 0.07 98.5 ± 5.3 104.3 ± 2.1 97.7 ± 1.9 
VLDL, mg/dL
§
 0.16 0.55 0.40 1.30 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.17 0.40 0.19 119.7 ± 6.0 126.6 ± 2.3 121.0 ± 2.2 
 
FADS2-rs1535
1
 Means ± SE 
 R2 
p-value 
EPA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.11 0.70 0.16 170.3 ± 7.3 178.1 ± 2.6 171.3 ± 2.5 
HDL-C, mg/dL 0.09 0.51 0.99 49.6 ± 2.5 49.8 ± 0.92 49.8 ± 0.8 
TG, mg/dL
§
 0.16 0.59 0.45 1.98 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.12 0.25 0.08 100.4 ± 5.7 104.1 ± 2.1 97.7 ± 1.9 
VLDL, mg/dL
§
 0.16 0.59 0.45 1.28 ± 0.04 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.18 0.42 0.19 120.6 ± 6.4 126.6 ± 2.3 120.9 ± 2.2 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and eicosapentaenoic 
acid (EPA). 
2
P-values for differences in lipid concentrations with assumption of an additive 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
EPA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.106 0.73 0.12 177.0 ± 2.5 171.5 ± 2.5 
HDL-C, mg/dL 0.096 0.52 0.99 49.9 ± 0.8 49.9 ± 0.9 
TG, mg/dL
§
 0.16 0.55 0.18 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.13 0.25 0.04 103.5 ± 1.9 97.7 ± 1.95 
VLDL, mg/dL
§
 0.16 0.55 0.18 1.3 ± 0.01 1.33 ± 0.013 
Non-HDL-C, mg/dL 0.17 0.44 0.13 125.7 ± 2.2 121.0 ± 2.2 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
EPA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.11 0.75 0.09 177.2 ± 2.5 171.3 ± 2.5 
HDL-C, mg/dL 0.093 0.50 0.99 49.82 ± 0.86 49.82 ± 0.86 
TG, mg/dL
§
 0.16 0.56 0.27 2.0 ± 0.012 2.02 ± 0.012 
LDL-C, mg/dL 0.13 0.26 0.03 103.7 ± 2.0 97.7 ± 1.95 
VLDL, mg/dL
§
 0.16 0.56 0.27 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.17 0.45 0.11 125.9 ± 2.2 120.9 ± 2.2 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and eicosapentaenoic 
acid (EPA). 
2
P-values for differences in lipid concentrations with assumption of dominant 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
DPA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 
0.10 0.01 0.055 166.7 ± 6.4 176.8 ± 2.4 169.4 ± 2.3 
HDL-C, mg/dL 
0.10 0.26 0.97 49.6 ± 2.2 49.3 ± 0.86 49.6 ± 0.8 
TG, mg/dL
§
 
0.16 0.56 0.42 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.12 0.005 0.02 96.7 ± 5.0 103.6 ± 1.9 96.4 ± 1.8 
VLDL, mg/dL
§
 
0.16 0.56 0.42 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 
0.17 0.02 0.05 117.1 ± 5.6 126.0.± 2.2 119.2 ± 2.0 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
DPA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 
0.103 0.01 0.04 167.0 ± 7.0 177.0 ± 2.4 169.0 ±  2.3 
HDL-C, mg/dL 
0.097 0.26 0.98 48.9 ± 2.5 49.4 ± 0.86 49.4 ± 0.8 
TG, mg/dL
§
 
0.16 0.57 0.42 1.96 ± 0.03 2.00 ± 0.01 2.01 ± 0.01 
LDL-C, mg/dL 
0.12 0.005 0.02 98.4 ± 5.4 103.5 ± 1.9 96.2 ± 1.8 
VLDL, mg/dL
§
 
0.16 0.57 0.42 1.27 ± 0.03 1.31 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 
0.17 0.02 0.05 118.2 ± 6.2 126.0 ± 2.2 119.0 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and docosapentaenoic 
acid (DPA). 
2
P-values for differences in lipid concentrations with assumption of an additive 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
DPA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 
0.096 0.01 0.06 175.5 ± 2.3 169.3 ± 2.3 
HDL-C, mg/dL 
0.100 0.25 0.84 49.4 ± 0.8 49.6 ± 0.8 
TG, mg/dL
§
 
0.16 0.53 0.32 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.12 0.01 0.01 102.7 ± 1.8 96.4 ± 1.8 
VLDL, mg/dL
§
 
0.16 0.53 0.32 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 
0.16 0.03 0.05 124.9 ± 2.03 119.2 ± 2.02 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
DPA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 
0.099 0.01 0.03 175.9 ± 2.3 169.0 ± 2.3 
HDL-C, mg/dL 
0.097 0.26 0.97 49.4 ± 0.81 49.4 ± 0.8 
TG, mg/dL
§
 
0.16 0.52 0.53 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 
0.12 0.006 0.009 102.9 ± 1.8 96.2 ± 1.77 
VLDL, mg/dL
§
 
0.16 0.52 0.53 1.30 ± 0.012 1.32 ± 0.012 
Non-HDL-C, mg/dL 
0.16 0.03 0.03 125.2 ± 2.05 119.0 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and docosapentaenoic 
acid (DPA). 
2
P-values for differences in lipid concentrations with assumption of dominant 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-
value 
DHA 
2
p-value 
SNP 
CC CT TT 
TC, mg/dL 
0.10 0.02 0.05 167.3 ± 6.4 177.3 ± 2.5 169.5 ± 2.3 
HDL-C, mg/dL 
0.10 0.19 0.98 49.7 ± 2.2 49.6 ± 0.87 49.4 ± 0.8 
TG, mg/dL
§
 
0.16 0.87 0.35 1.97 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 
0.12 0.02 0.03 97.1 ± 5.0 103.8 ± 2.0 96.7 ± 1.8 
VLDL, mg/dL
§
 
0.16 0.87 0.35 1.27 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 
0.16 0.05 0.06 117.5 ± 5.6 126.2 ± 2.2 119.5 ± 2.1 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-
value 
DHA 
2
p-value 
SNP 
AA GA GG 
TC, mg/dL 0.10 0.02 0.04 167.6 ± 7.0 177.4 ± 2.5 169.2 ±  2.3 
HDL-C, mg/dL 0.102 0.19 0.91 49.0 ± 2.4 49.7 ± 0.87 49.2 ± 0.8 
TG, mg/dL
§
 0.16 0.88 0.38 1.96 ± 0.03 2.00 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.12 0.02 0.03 98.9 ± 5.5 103.7±1.96 96.5 ± 1.8 
VLDL, mg/dL
§
 0.16 0.88 0.38 1.26 ± 0.03 1.30 ± 0.01 1.32 ± 0.01 
Non-HDL-C, mg/dL 0.165 0.05 0.07 118.6 ± 6.2 126.2 ± 2.2 119.4 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and docosahexaenoic 
acid (DHA). 
2
P-values for differences in lipid concentrations with assumption of an additive 
genetic model. 
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FADS1-rs174546
1
 Means ± SE 
 R
2
 
p-value 
DHA 
2
p-value 
SNP 
CC + CT TT 
TC, mg/dL 0.10 0.03 0.051 175.9 ± 2.3 169.5 ± 2.34 
HDL-C, mg/dL 0.10 0.18 0.86 49.6 ± 0.8 49.4 ± 0.8 
TG, mg/dL
§
 0.16 0.85 0.25 2.0 ± 0.01 2.02 ± 0.01 
LDL-C, mg/dL 0.12 0.02 0.02 102.9 ± 1.8 96.7 ± 1.82 
VLDL, mg/dL
§
 0.16 0.85 0.25 1.3 ± 0.011 1.32 ± 0.012 
Non-HDL-C, mg/dL 0.16 0.05 0.06 125.0 ± 2.07 119.5 ± 2.06 
 
FADS2-rs1535
1
 Means ± SE 
 R
2
 
p-value 
DHA 
2
p-value 
SNP 
AA+AG GG 
TC, mg/dL 0.01 0.03 0.03 176.3 ± 2.4 169.2 ± 2.3 
HDL-C, mg/dL 0.10 0.19 0.74 49.6 ± 0.82 49.2 ± 0.8 
TG, mg/dL
§
 0.16 0.85 0.44 2.0 ± 0.012 2.01 ± 0.012 
LDL-C, mg/dL 0.12 0.02 0.01 103.1 ± 1.8 96.5 ± 1.8 
VLDL, mg/dL
§
 0.16 0.85 0.44 1.30 ± 0.012 1.32± 0.012 
Non-HDL-C, mg/dL 0.16 0.06 0.04 125.3 ± 2.09 119.3 ± 2.0 
 
All variables are adjusted means ± standard error. 
§
Log-transformed values 
1
Models were adjusted for sex, age, age
2
, age
3
, BMI, total energy intake and docosahexaenoic 
acid (DHA). 
2
P-values for differences in lipid concentrations with assumption of dominant 
genetic model. 
